formed policy decisions under sections 1004 and 
1005; and 
‘‘(C) other duties as may be determined by 
the Director with respect to measuring or as-
sessing performance or agency budgets. 
‘‘(2) DETERMINATION OF POSITION.—The Di-
rector shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive 
Service or a career appointee at the GS–15 level (or 
equivalent) or above. 
‘‘§ 1007. Monitoring and evaluation of national drug 
control program 
‘‘(a) IN GENERAL.—The Director shall monitor im-
plementation of the National Drug Control Program and 
the activities of the National Drug Control Program Agen-
cies in carrying out the goals and objectives of the Na-
tional Drug Control Strategy including— 
‘‘(1) conducting program and performance au-
dits and evaluations; and 
‘‘(2) requesting assistance from the Inspector 
General of the relevant agency in such audits and 
evaluations. 
‘‘(b) ACCOUNTING OF FUNDS EXPENDED.—(1) Not 
later than February 1 of each year, in accordance with 
guidance issued by the Director, the head of each National
Drug Control Program Agency shall submit to the Direc-
tor a detailed accounting of all funds expended by the 
agency for National Drug Control Program activities dur-
ing the previous fiscal year and shall ensure such detailed 
accounting is authenticated for the previous fiscal year by 
the Inspector General for such agency prior to the submis-
sion to the Director as frequently as determined by the 
Inspector General but not less frequently that every 3 
years. 
‘‘(2) The Director shall submit to Congress not later 
than April 1 of each year the information submitted to 
the Director under paragraph (1). 
‘‘(c) NOTIFICATION.—The Director shall notify any 
National Drug Control Program Agency if its activities 
are not in compliance with the responsibilities of the agen-
cy under the National Drug Control Strategy, transmit 
a copy of each such notification to the President and the 
appropriate congressional committees, and maintain a 
copy of each such notification. 
‘‘(d) RECOMMENDATIONS.—The Director shall make 
such recommendations to the President and the appro-
priate congressional committees as the Director deter-
mines are appropriate regarding changes in the organiza-
tion, management, and budgets of the National Drug Con-
trol Program Agencies, and changes in the allocation of
personnel to and within those agencies, to implement the 
policies, goals, objectives, and priorities established under 
section 1002(c)(1) and the National Drug Control Strat-
egy. 
‘‘(e) AUTHORIZATION, DEVELOPMENT, AND IMPLE-
MENTATION OF A COORDINATED TRACKING SYSTEM.— 
‘‘(1) ESTABLISHMENT.—The Director shall es-
tablish a coordinated tracking system of federally- 
funded initiatives and grant programs which shall— 
‘‘(A) be the central repository of all drug 
control grants; 
‘‘(B) identify duplication, overlap, or gaps 
in funding to provide increased accountability of 
federally-funded grants for substance use dis-
order treatment, prevention, and enforcement; 
‘‘(C) identify impediments that applicants 
currently have in the grant application process 
with applicable agencies; and 
‘‘(D) be developed and maintained by the 
Office with the support of designated National 
Drug Control Program Agencies and any other 
agency determined by the Director. 
‘‘(2) PERFORMANCE
METRICS.—The Director 
shall identify metrics and achievable goals for grant 
recipients in furtherance of the Strategy. Such
metrics shall be used to measure how effective each 
federally funded initiative is in achieving the objec-
tives of the Strategy and to enable comparisons of 
federally funded initiatives to identify those that are 
the most cost effective. 
‘‘(3) 
GRANT
APPLICATION
STANDARDIZA-
TION.—To reduce the administrative burden on 
grant applicants and improve oversight of Federal 
funds, the Director, in consultation with the head of 
each National Drug Control Program Agency, shall 
develop a plan for coordinating and standardizing 
drug control grant application processes and develop 
a joint application to be used by all National Drug 
Control Program Agencies. 
‘‘(4) CENTRAL
PORTAL.—The Director shall 
maintain on the public, electronic portal of the Of-
fice a list all drug control grant programs available 
in a central location. The head of each National 
Drug Control Program Agency shall provide a com-
plete list of all drug control program grant programs 
to the Director and annually update such list. 
‘‘(5) REPORT
TO
CONGRESS.—The Director 
shall include in the assessment submitted to Con-
gress under section 1006 an assessment on progress 
under this section.
‘‘§ 1008. Coordination and oversight of the national 
drug control program 
‘‘(a) IN GENERAL.—The Director shall coordinate 
and oversee the implementation by the National Drug 
Control Program Agencies of the policies, goals, objectives, 
and priorities established under section 1002(c)(1) and 
the fulfillment of the responsibilities of such agencies 
under the National Drug Control Strategy and make rec-
ommendations to National Drug Control Program Agency 
heads with respect to implementation of National Drug 
Control Programs. 
‘‘(b) DETAILING EMPLOYEES
TO OTHER AGEN-
CIES.— 
‘‘(1) REQUEST.—The Director may request the 
head of an agency or program of the Federal Gov-
ernment to place agency personnel who are engaged 
in drug control activities on temporary detail to an-
other agency in order to implement the National 
Drug Control Strategy. 
‘‘(2) AGENCY COMPLIANCE.—The head of the 
agency shall comply with any request made under 
paragraph (1). 
‘‘(3) MAXIMUM NUMBER OF DETAILEES.—The 
maximum number of personnel who may be detailed 
to another agency (including the Office) under this 
subsection during any fiscal year is—
‘‘(A) for the Department of Defense, 50; 
and 
‘‘(B) for any other agency, 10. 
‘‘(c) DIRECTING FEDERAL FUNDING.—The Director 
may transfer funds made available to a National Drug 
Control Program Agency for National Drug Control Strat-
egy programs and activities to another account within 
such agency or to another National Drug Control Program 
Agency for National Drug Control Strategy programs and 
activities, except that— 
‘‘(1) the authority under this subsection may be 
limited in an annual appropriations Act or other 
provision of Federal law; 
‘‘(2) the Director may exercise the authority 
under this subsection only with the concurrence of 
the head of each affected agency; 
‘‘(3) in the case of an interagency transfer, the 
total amount of transfers under this subsection may 
not exceed 3 percent of the total amount of funds 
made available for National Drug Control Strategy 
programs and activities to the agency from which 
those funds are to be transferred; 
‘‘(4) funds transferred to an agency under this 
subsection may only be used to increase the funding 
for programs or activities authorized by law;
‘‘(5) the Director shall— 
‘‘(A) submit to the appropriate congres-
sional committees and any other applicable 
committee of jurisdiction, a reprogramming or 
transfer request in advance of any transfer 
under this subsection in accordance with the 
regulations of each affected agency; and 
‘‘(B) annually submit to the appropriate 
congressional committees a report describing 
the effect of all transfers of funds made pursu-
ant to this subsection or section 1004(f) during 
the 12-month period preceding the date on 
which the report is submitted; and 
‘‘(6) funds may only be used for— 
‘‘(A) expansion of demand reduction activi-
ties; 
‘‘(B) interdiction of illicit drugs on the 
high seas, in United States territorial waters, 
and at United States ports of entry by officers 
and employees of National Drug Control Pro-
gram Agencies and domestic and foreign law 
enforcement officers; 
‘‘(C) accurate assessment and monitoring 
of international drug production and interdic-
tion programs and policies;
‘‘(D) activities to facilitate and enhance 
the sharing of domestic and foreign intelligence 
information among National Drug Control Pro-
gram Agencies related to the production and 
trafficking of drugs in the United States and 
foreign countries; 
‘‘(E) activities to prevent the diversion of 
prescription drugs for illicit use; and 
‘‘(F) research related to any of these ac-
tivities. 
‘‘(d) DIRECTING FEDERAL FUNDING TO RESPOND 
TO EMERGING THREATS.— 
‘‘(1) IN GENERAL.—The Director may transfer 
funds made available to a National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to another account within 
such agency or to another National Drug Control 
Program Agency for National Drug Control Strategy 
programs and activities to implement the provisions 
of a plan developed under section 1009, except 
that— 
‘‘(A) the authority under this subsection 
may be limited in an annual appropriations Act 
or other provision of Federal law;
‘‘(B) the Director may exercise the author-
ity under this subsection only with the concur-
rence of the head of each affected agency; 
‘‘(C) in the case of an interagency transfer, 
the total amount of transfers under this sub-
section may not exceed 10 percent of the total 
amount of funds made available for National 
Drug Control Strategy programs and activities 
to the agency from which those funds are to be 
transferred; 
‘‘(D) funds transferred to an agency under 
this subsection may only be used to increase the 
funding for programs or activities authorized by 
law; 
‘‘(E) no transfer of funds under this sub-
section may result in a reduction in total Fed-
eral expenditures for substance use disorder 
treatment; 
‘‘(F) the Director shall— 
‘‘(i) submit to the appropriate con-
gressional committees and any other appli-
cable committee of jurisdiction, a re-
programming or transfer request in ad-
vance of any transfer under this subsection
in accordance with the regulations of each 
affected agency; and 
‘‘(ii) annually submit to the appro-
priate congressional committees a report 
describing the effect of all transfers of 
funds made pursuant to this subsection or 
section 1004(f) during the 12-month pe-
riod preceding the date on which the report 
is submitted; and 
‘‘(G) funds may only be used for— 
‘‘(i) expansion of demand reduction 
activities; 
‘‘(ii) interdiction of illicit drugs on the 
high seas, in United States territorial 
waters, and at United States ports of entry 
by officers and employees of National 
Drug Control Program Agencies and do-
mestic and foreign law enforcement offi-
cers; 
‘‘(iii) accurate assessment and moni-
toring of international drug production and 
interdiction programs and policies; 
‘‘(iv) activities to facilitate and en-
hance the sharing of domestic and foreign 
intelligence information among National
Drug Control Program Agencies related to 
the production and trafficking of drugs in 
the United States and foreign countries; 
‘‘(v) activities to prevent the diversion 
of prescription drugs for illicit use; and 
‘‘(vi) research related to any of these 
activities. 
‘‘(2) INADEQUACY OF TRANSFER.—In the event 
the authority under this subsection is inadequate to 
implement the provisions of a plan developed under 
section 1009, the Director shall submit a request for 
funding to the appropriate congressional committees 
within 30 days after the date on which the Director 
determines there is a need for additional funding. 
‘‘(e) FUND CONTROL NOTICES.— 
‘‘(1) IN GENERAL.—The Director may issue to 
the head of a National Drug Control Program Agen-
cy a fund control notice to ensure compliance with 
the National Drug Control Program Strategy. A 
fund control notice may direct that all or part of an 
amount appropriated to the National Drug Control 
Program Agency account be obligated by— 
‘‘(A) months, fiscal year quarters, or other 
time periods; and
‘‘(B) activities, functions, projects, or ob-
ject classes. 
‘‘(2) UNAUTHORIZED OBLIGATION OR EXPENDI-
TURE
PROHIBITED.—An officer or employee of a 
National Drug Control Program Agency shall not 
make or authorize an expenditure or obligation con-
trary to a fund control notice issued by the Director. 
‘‘(3) DISCIPLINARY ACTION FOR VIOLATION.— 
In the case of a violation of paragraph (2) by an of-
ficer or employee of a National Drug Control Pro-
gram Agency, the head of the agency, upon the re-
quest of and in consultation with the Director, may 
subject the officer or employee to appropriate ad-
ministrative 
discipline, 
including, 
when 
cir-
cumstances warrant, suspension from duty without 
pay or removal from office. 
‘‘(4) CONGRESSIONAL NOTICE.—Not later than 
5 days after issuance of a fund control notice, the 
Director shall submit a copy of such fund control 
notice to the appropriate congressional committees 
and make such notice publicly available. 
‘‘(5) RESTRICTIONS.—The Director may not 
issue a fund control notice to direct that all or part 
of an amount appropriated to the National Drug 
Control Program Agency account be obligated, modi-
fied, or altered in any manner contrary, in whole or 
in part, to a specific appropriation or statute. 
‘‘(f) EXCLUSIONS.—The authorities described under 
subsections (c), (d), and (e) do not apply to any program 
under subchapter II or III. 
‘‘(g) FOREIGN ASSISTANCE ACT PARTICIPATION.— 
The Director may participate in the drug certification 
process pursuant to section 490 of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2291j) and section 706 of the 
Department of State Authorization Act for Fiscal Year 
2003 (22 U.S.C. 229j–l). 
‘‘(h) CERTIFICATIONS OF POLICY CHANGES TO DI-
RECTOR.— 
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
the head of a National Drug Control Program Agen-
cy shall, unless exigent circumstances require other-
wise, notify the Director in writing regarding any 
proposed change in policies relating to the activities 
of that agency under the National Drug Control 
Program prior to implementation of such change. 
The Director shall promptly review such proposed 
change and certify to the head of that agency in 
writing whether such change is consistent with the 
National Drug Control Strategy.
‘‘(2) EXCEPTION.—If prior notice of a proposed 
change under paragraph (1) is not practicable— 
‘‘(A) the head of the National Drug Con-
trol Program Agency shall notify the Director 
of the proposed change as soon as practicable; 
and 
‘‘(B) upon such notification, the Director 
shall review the change and certify to the head 
of that agency in writing whether the change is 
consistent with the National Drug Control 
Strategy. 
‘‘(i) WORK IN CONJUNCTION WITH ASSISTANT FOR 
NATIONAL SECURITY AFFAIRS.—The Director shall, in 
any matter affecting national security interests, work in 
conjunction with the Assistant to the President for Na-
tional Security Affairs. 
‘‘(j) AUTHORITIES NOT DEROGATED.—Nothing in 
this chapter shall be construed as derogating the authori-
ties and responsibilities of the head of any agency, the Di-
rector of National Intelligence, or the Director of the Cen-
tral Intelligence Agency contained in the National Security 
Act of 1947 (50 U.S.C. 401 et seq.), the Central Intel-
ligence Agency Act of 1949 (50 U.S.C. 403a et seq.), or 
any other law.
‘‘§ 1009. Emerging threats task force, plan, campaign 
‘‘(a) EMERGING THREATS TASK FORCE.— 
‘‘(1) EMERGING AND CONTINUING THREATS CO-
ORDINATOR.—The Director shall designate or ap-
point a United States Emerging and Continuing 
Threats Coordinator to perform the duties of that 
position described in this section and such other du-
ties as may be determined by the Director. The Di-
rector shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive 
Service or a career appointee at the GS–15 level (or 
equivalent) or above. 
‘‘(2) ESTABLISHMENT AND MONITORING.—The 
Emerging and Continuing Threats Coordinator (re-
ferred to in this section as the ‘Coordinator’) shall 
monitor evolving and emerging drug threats in the 
United States and shall serve as Chair of an Emerg-
ing Threats Task Force (in this section, referred to 
as the ‘task force’). The Director shall appoint other 
members of the task force, which shall include— 
‘‘(A) representatives from National Drug 
Control Program Agencies or other agencies; 
‘‘(B) representatives from State, local, and 
Tribal governments;
‘‘(C) the Director of the National Drug 
Control Fusion Center established in section 
1013; and 
‘‘(D) representatives from other entities as 
determined to be necessary by the Director. 
‘‘(3) INFORMATION REVIEW AND SHARING.— 
‘‘(A) IN GENERAL.—The task force shall 
disseminate and facilitate the sharing with Fed-
eral, State, local, and Tribal officials and other 
entities as determined by the Director of perti-
nent information and data relating to the fol-
lowing: 
‘‘(i) Recent trends in drug supply and 
demand. 
‘‘(ii) Fatal and nonfatal overdoses. 
‘‘(iii) Demand for and availability of 
evidence-based 
substance 
use 
disorder 
treatment, including the extent of the 
unmet treatment need, and treatment ad-
mission trends. 
‘‘(iv) Recent trends in drug interdic-
tion, supply, and demand from State, local, 
and Tribal law enforcement agencies. 
‘‘(v) Other subject matter as deter-
mined necessary by the Director.
‘‘(B) CONTRACT, AGREEMENT, AND OTHER 
AUTHORITY.—The Director may award con-
tracts, enter into interagency agreements, man-
age individual projects, and conduct other ac-
tivities in support of the identification of emerg-
ing drug threats and in support of the develop-
ment, implementation, and assessment of any 
Emerging Threat Response Plan. 
‘‘(C) DATA ANALYSIS ACTIVITIES.—In sup-
port of the task force, the National Drug Con-
trol Fusion Center is authorized to conduct and 
provide to the task force the results of data 
analysis activities that the task force requests 
to aid in their review of recent trends in the 
data disseminated under subparagraph (A). 
‘‘(4) CRITERIA TO IDENTIFY EMERGING DRUG 
THREATS.—Not later than 60 days after the date on 
which a task force first meets, the task force shall 
develop and recommend to the Director criteria to be 
used to identify an emerging drug threat or the ter-
mination of an emerging drug threat designation 
based on information gathered by the task force in 
paragraph (2), statistical data, and other evidence. 
‘‘(5) MEETINGS.—The task force shall meet in 
person not less frequently than quarterly and at ad-
ditional meetings if determined to be necessary by 
and at the call of the Chair to— 
‘‘(A) identify and discuss evolving and 
emerging drug trends in the United States 
using the criteria established in paragraph (3); 
‘‘(B) assist in the formulation of any plan 
described in subsection (c); 
‘‘(C) oversee implementation of the plan 
described in subsection (c); and 
‘‘(D) provide such other advice to the Co-
ordinator and Director concerning strategy and 
policies for emerging drug threats and trends as 
the task force determines to be appropriate. 
‘‘(b) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consulta-
tion with the Coordinator, the task force, and the 
head of each National Drug Control Program Agen-
cy, may designate an emerging drug threat in the 
United States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Di-
rector, in consultation with the Coordinator, shall 
promulgate and make publicly available standards by 
which a designation under paragraph (1) and the 
termination of such designation may be made. In de-
veloping such standards, the Director shall consider
the recommendations of the task force and other cri-
teria the Director considers to be appropriate. 
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di-
rector shall publish a public written statement on 
the portal of the Office explaining the designation of 
an emerging drug threat or the termination of such 
designation and shall notify the appropriate congres-
sional committees of the availability of such state-
ment when a designation or termination of such des-
ignation has been made. 
‘‘(c) PLAN.— 
‘‘(1) PUBLIC
AVAILABILITY
OF
PLAN.—Not 
later than 60 days after making a designation under 
subsection (b), the Director shall publish and make 
publicly available an Emerging Threat Response 
Plan and notify the President and the appropriate 
congressional committees of such plan’s availability. 
‘‘(2) TIMING.—Not less frequently than every 
90 days after the date on which the plan is pub-
lished under paragraph (1), the Director shall up-
date the plan and report on implementation of the 
plan, until the Director issues the public statement 
required under subsection (b)(3) to terminate the 
emerging drug threat designation.
additional appropriations are necessary to im-
plement the plan; 
‘‘(E) an implementation strategy for the 
education and public awareness campaign under 
subsection (d), including goals as described 
under subparagraph (B) and performance 
measures, objectives, and targets, as described 
under subparagraph (C); and 
‘‘(F) any other information necessary to 
inform the public of the status, progress, or re-
sponse of an emerging drug threat. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN
GENERAL.—Not later than 90 
days after the date on which a designation is 
made under subsection (b), the Director, in 
consultation with the President, the appropriate 
congressional committees, and the head of each 
National Drug Control Program Agency, shall 
issue guidance on implementation of the plan 
described in this subsection to the National 
Drug Control Program Agencies and any other 
relevant agency determined to be necessary by 
the Director. 
‘‘(B) 
COORDINATOR’S
RESPONSIBIL-
ITIES.—The Coordinator shall—
‘‘(i) direct the implementation of the 
plan among the agencies identified in the 
plan, State, local, and Tribal governments, 
and other relevant entities; 
‘‘(ii) facilitate information-sharing be-
tween agencies identified in the plan, 
State, local, and Tribal governments, and 
other relevant entities; and 
‘‘(iii) monitor implementation of the 
plan by coordinating the development and 
implementation of collection and reporting 
systems to support performance measure-
ment and adherence to the plan by agen-
cies identified in plan, where appropriate. 
‘‘(C) REPORTING.—Not later than 180 
days after the date on which a designation is 
made under subsection (b) and in accordance 
with paragraph (2)(C), the head of each agency 
identified in the plan shall submit to the Coor-
dinator a report on implementation of the plan. 
‘‘(d) EDUCATION
AND PUBLIC AWARENESS CAM-
PAIGN FOR EMERGING DRUG THREATS.— 
‘‘(1) IN
GENERAL.—Not later than 90 days 
after the date on which a designation is made under 
subsection (b), the Director shall, to the extent fea-
sible and appropriate, establish and implement an 
evidence-based substance use prevention education 
and public awareness campaign to inform the public 
about the dangers of any drug designated as an 
emerging drug threat. Such campaign shall— 
‘‘(A) educate the public about the dangers 
of such drug, including patient and family edu-
cation about the characteristics and hazards of 
such drug and methods to safeguard against 
such dangers, including the safe disposal of 
such drug; 
‘‘(B) support evidence-based prevention 
programs targeting audiences’ attitudes, percep-
tions, and beliefs concerning substance use and 
intentions to initiate or continue such use; 
‘‘(C) increase awareness of the negative 
consequences of drug use; 
‘‘(D) encourage individuals affected by 
substance use disorders to seek treatment and 
provide such individuals with information on 
how to recognize addiction issues, what forms 
of evidence-based treatment options are avail-
able, and how to access such treatment; and 
‘‘(E) combat the stigma of addiction and 
substance use disorders, including the stigma of
treating such disorders with medication-assisted 
treatment therapies. 
‘‘(2) CONSULTATION.—For the planning of the 
campaign under paragraph (1), the Director shall 
consult with— 
‘‘(A) the head of any appropriate National 
Drug Control Program Agency to obtain advice 
on evidence-based scientific information for pol-
icy, program development, and evaluation; 
‘‘(B) experts in evidence-based media cam-
paigns, education, evaluation, and communica-
tion; 
‘‘(C) experts on the designated drug; 
‘‘(D) State, local, and Tribal government 
officials and relevant agencies; 
‘‘(E) the public; 
‘‘(F) appropriate congressional committees; 
and 
‘‘(G) any other affected person, as deter-
mined by the Director. 
‘‘(3) GIFTS AND DONATIONS.— 
‘‘(A) IN GENERAL.—The Director may ac-
cept gifts and donations (in cash or in kind, in-
cluding voluntary and uncompensated services 
or property), which shall be available until ex-
pended, for the purpose of supporting the edu-
cation and public awareness campaign author-
ized in this section, including the media cam-
paign. 
‘‘(B) ETHICS GUIDELINES.—The Director 
shall establish written guidelines setting forth 
the criteria to be used in determining whether 
a gift or donation should be declined under this 
section because the acceptance of the gift or do-
nation would— 
‘‘(i) reflect unfavorably upon the abil-
ity of the Director or the Office, or any 
employee of the Office, to carry out re-
sponsibilities or official duties under this 
chapter in a fair and objective manner; or 
‘‘(ii) compromise the integrity or the 
appearance of integrity of programs or 
services provided under this chapter or of 
any official involved in those programs or 
services. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN GENERAL.—For any campaign es-
tablished under this subsection, the Director 
shall ensure the following:
‘‘(i) Implementation is evidence-based, 
meets accepted standards for public aware-
ness campaigns, and uses available re-
sources in a manner to make the most 
progress toward achieving the goals identi-
fied in the Emerging Threats Response 
Plan and the requirements of paragraph 
(1). 
‘‘(ii) 
Information 
disseminated 
through the campaign is accurate. 
‘‘(iii) The Director approves the strat-
egy of the campaign, all material distrib-
uted through the campaign, and the use of 
any Federal funds used for the campaign. 
‘‘(iv) The campaign is designed using 
strategies found to be most effective at 
achieving such goals and requirements of 
paragraph (1), which may include— 
‘‘(I) a media campaign, as de-
scribed in subparagraph (B); 
‘‘(II) local, regional, or popu-
lation specific messaging; 
‘‘(III) establishing partnerships 
and promoting coordination among 
community 
stakeholders, 
including
public, nonprofit organizations, and 
for profit entities; 
‘‘(IV) providing support, train-
ing, and technical assistance to estab-
lish and expand school and commu-
nity prevention programs; 
‘‘(V) creating websites to pub-
licize and disseminate information; 
‘‘(VI) conducting outreach and 
providing educational resources for 
parents; 
‘‘(VII) establishing State or re-
gional advisory councils to provide 
input and recommendations to raise 
awareness regarding the drug des-
ignated as an emerging drug threat; 
‘‘(VIII) collaborating with law 
enforcement; and 
‘‘(IX) support for school-based 
public health education classes to im-
prove teen knowledge about the effects 
of such designated drug. 
‘‘(B) MEDIA
CAMPAIGN.—Any campaign 
implemented under this subsection may include 
a media component, which—
‘‘(i) shall be designed to prevent the 
use of the drug designated as an emerging 
drug threat and to achieve the goals and 
requirements of paragraph (1); 
‘‘(ii) shall be carried out through com-
petitively awarded contracts to entities pro-
viding for the professional production and 
design of such campaign; and 
‘‘(iii) may include the use of tele-
vision, radio, Internet, social media, and 
other commercial marketing venues and 
may be targeted to specific age groups 
based on peer-reviewed social research. 
‘‘(C) REQUIRED NOTICE FOR COMMUNICA-
TION FROM THE OFFICE.—Any communication, 
including an advertisement, paid for or other-
wise disseminated by the Office directly or 
through a contract awarded by the Office shall 
include a prominent notice informing the audi-
ence that the communication was paid for by of 
the Office. 
‘‘(5) EVALUATION.— 
‘‘(A) PERFORMANCE
EVALUATION.—The 
Director shall include an evaluation of the cam-
paign in the annual assessment under section 
1006, which shall include the following: 
‘‘(i) A performance evaluation of the 
campaign, including progress toward meet-
ing the goals, objectives, measures, and 
targets identified in the Emerging Threats 
Response Plan. 
‘‘(ii) A description of all policies and 
practices to eliminate the potential for 
waste, fraud, abuse, and to ensure Federal 
funds are used responsibly. 
‘‘(iii) A list of all contracts or other 
agreements entered into to implement the 
campaign. 
‘‘(iv) The results of any financial 
audit of the campaign. 
‘‘(v) A description of any evidence 
used to develop the campaign. 
‘‘(vi) The sources and amount of each 
gift or donation accepted by the Office, 
and the source and amount of each gift or 
donation accepted by a contractor to be 
used in its performance of a contract for 
the campaign.
‘‘(B) INDEPENDENT
EVALUATION.—Not 
later than 180 days after establishing a cam-
paign under paragraph (1) and not less than 
frequently than every 2 years thereafter, the 
Director shall— 
‘‘(i) designate an independent entity 
to evaluate the effectiveness of the cam-
paign with meeting the goals established in 
the Emerging Threat Response Plan and 
the requirements of paragraph (1); and 
‘‘(ii) submit the results of the inde-
pendent evaluation to the appropriate con-
gressional committees. 
‘‘(6) FUNDING
PROHIBITIONS.—None of the 
amounts made available under this subsection may 
be obligated for any of the following: 
‘‘(A) To supplant current anti-drug com-
munity-based coalitions. 
‘‘(B) To supplant pro bono public service 
time donated by national and local broadcasting 
network for other public services campaigns. 
‘‘(C) For partisan political purposes, or ex-
press advocacy in support of or to defeat any 
clearly identified candidate, clearly identified
ballot initiative, or clearly identified legislative 
or regulatory proposal. 
‘‘(D) For any advocacy in support of any 
particular company, industry association, or ad-
vocacy group or the explicit policy positions 
held by such groups. 
‘‘(E) To direct any individuals to a specific 
type of substance use disorder treatment, treat-
ment facility, medical provider, or form of medi-
cation assisted treatment. 
‘‘(F) To fund any advertising that features 
any elected officials, persons seeking elected of-
fice, cabinet level officials, or other Federal offi-
cials employed pursuant to section 213 of 
Schedule C of title 5, Code of Federal Regula-
tions. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to the Office to carry out 
this section, $25 million for each of fiscal years 2019 
through 2023. 
‘‘§ 1010. National and international coordination 
‘‘(a) DISSEMINATION OF RESEARCH AND INFORMA-
TION TO STATES.—The Director shall ensure that drug 
control research and information is effectively dissemi-
nated by National Drug Control Program Agencies to
State and local governments and nongovernmental entities 
involved in demand reduction by— 
‘‘(1) encouraging formal consultation between 
any such agency that conducts or sponsors research, 
and any such agency that disseminates information 
in developing research and information product de-
velopment agendas; 
‘‘(2) encouraging such agencies (as appropriate) 
to develop and implement dissemination plans that 
specifically target State and local governments and 
nongovernmental entities involved in demand reduc-
tion; and 
‘‘(3) supporting the substance abuse informa-
tion clearinghouse administered by the Assistant 
Secretary for Mental Health and Substance Use and 
established in section 501(d)(16) of the Public 
Health Service Act by— 
‘‘(A) encouraging all National Drug Con-
trol Program Agencies to provide all appro-
priate and relevant information; and 
‘‘(B) supporting the dissemination of infor-
mation to all interested entities. 
‘‘(b) STANDARDS.— 
‘‘(1) DEVELOPMENT.—The Director shall co-
ordinate the development of evidence-based stand-
ards developed by National Drug Control Program 
Agencies and other relevant agencies and non-Fed-
eral entities to State, local, and Tribal governments 
and nongovernmental entities related to drug control 
policies, practices, and procedures, such as the inves-
tigation of drug-related deaths, by— 
‘‘(A) encouraging appropriate agencies and 
State, local, and Tribal governments to develop 
data standards for drug control practices and 
procedures and related statistical data; 
‘‘(B) encouraging information sharing be-
tween appropriate agencies and State, local, 
and Tribal governments of relevant drug control 
information and data; 
‘‘(C) establishing a working group of agen-
cies, State, local, and Tribal governments, and 
other relevant stakeholders to discuss and de-
velop such standards; and 
‘‘(D) facilitating collaboration among agen-
cies, non-Federal entities, States, local, and 
Tribal 
governments, 
and 
nongovernmental 
agencies. 
‘‘(2) IMPLEMENTATION.—The Director shall 
promote the implementation of the standards de-
scribed in paragraph (1) by—
‘‘(A) encouraging adoption by providing 
the standards to State and local governments 
through the internet, annual publications or 
periodicals, 
and 
other 
widely-disseminated 
means; and 
‘‘(B) facilitating the use and dissemination 
of such standards among State and local gov-
ernments by— 
‘‘(i) providing technical assistance to 
State, local, and Tribal governments seek-
ing to adopt or implement such standards; 
and 
‘‘(ii) coordinating seminars and train-
ing sessions for State, local, and Tribal 
governments seeking to adopt or imple-
ment such standards. 
‘‘(c) PRIVATE SECTOR.— 
‘‘(1) IN GENERAL.—The Director or the head 
of a National Drug Control Program (as designated 
by the Director) shall coordinate with the private 
sector to promote private research and development 
of medications to treat or prevent addiction, includ-
ing research and development for non-addictive pain 
management medication, abuse deterrent formula-
tions, medication-assisted treatment, and other ad-
diction research determined to be necessary by the 
Director by— 
‘‘(A) encouraging the sharing of informa-
tion regarding evidence-based treatment addic-
tion findings and related data between agencies 
and the private sector, as appropriate; 
‘‘(B) encouraging collaboration between 
appropriate agencies and the private sector; and 
‘‘(C) providing private sector entities with 
relevant statistical data and information to en-
hance research as permissible. 
‘‘(2) WORKING GROUP.—The Director may es-
tablish a working group of National Drug Control 
Program Agencies, State, local, and Tribal govern-
ments, and the private sector stakeholders to discuss 
and disseminate best practices, research and devel-
opment, and other related issues, as appropriate. 
‘‘(d) MODEL ACTS PROGRAM.— 
‘‘(1) IN GENERAL.—The Director shall provide 
for or shall enter into an agreement with a nonprofit 
organization to— 
‘‘(A) advise States on establishing laws 
and policies to address illicit drug use issues; 
and
‘‘(B) revise such model State drug laws 
and draft supplementary model State laws to 
take into consideration changes in illicit drug 
use issues in the State involved. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $1.25 million for each of fiscal years 
2019 through 2023. 
‘‘(e) DRUG COURT TRAINING AND TECHNICAL AS-
SISTANCE PROGRAM.— 
‘‘(1) GRANTS AUTHORIZED.—The Director may 
make a grant to a nonprofit organization for the 
purpose of providing training and technical assist-
ance to drug courts. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $2 million for each of fiscal years 
2019 through 2023. 
‘‘(f) INTERNATIONAL COORDINATION.—The Director 
may facilitate international drug control coordination ef-
forts. 
‘‘(g) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI-
NATOR.—The Director shall designate or appoint a United 
States State, Local, and Tribal Affairs Coordinator to per-
form the duties of the Office outlined in this section and
section 1005 and such other duties as may be determined 
by the Director with respect to coordination of drug con-
trol efforts between agencies and State, local, and Tribal 
governments. The Director shall determine whether the 
coordinator position is a noncareer appointee in the Senior 
Executive Service or a career appointee at the GS–15 level 
(or equivalent) or above. 
‘‘§ 1011. Interdiction 
‘‘(a) UNITED
STATES
INTERDICTION
COORDI-
NATOR.— 
‘‘(1) IN
GENERAL.—The Director shall des-
ignate or appoint a noncareer appointee in the Sen-
ior Executive Service or a career appointee at the 
GS–15 level (or equivalent) or above as the United 
States Interdiction Coordinator to perform the du-
ties of that position described in paragraph (2) and 
such other duties as may be determined by the Di-
rector with respect to coordination of efforts to 
interdict illicit drugs from entering the United 
States. 
‘‘(2) RESPONSIBILITIES.—The United States 
Interdiction Coordinator shall be responsible to the 
Director for— 
‘‘(A) coordinating the interdiction activities 
of the National Drug Control Program Agen-
cies to ensure consistency with the National 
Drug Control Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before September 1 of each 
year and in accordance with paragraph (4), a 
National Interdiction Command and Control 
Plan to ensure the coordination and consistency 
described in subparagraph (A); 
‘‘(C) assessing the sufficiency of assets 
committed to illicit drug interdiction by the rel-
evant National Drug Control Program Agen-
cies; and 
‘‘(D) advising the Director on the efforts 
of each National Drug Control Program Agency 
to implement the National Interdiction Com-
mand and Control Plan. 
‘‘(3) STAFF.—The Director shall assign such 
permanent staff of the Office as he considers appro-
priate to assist the United States Interdiction Coor-
dinator to carry out the responsibilities described in 
paragraph (2), and may request that appropriate 
National Drug Control Program Agencies detail or 
assign staff to assist in carrying out such activities. 
‘‘(4) NATIONAL INTERDICTION COMMAND AND 
CONTROL PLAN.—
‘‘(A) PURPOSES.—The National Interdic-
tion Command and Control Plan— 
‘‘(i) shall set forth the Government’s 
strategy for drug interdiction; 
‘‘(ii) shall state the specific roles and 
responsibilities of the relevant National 
Drug Control Program Agencies for imple-
menting that strategy; and 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy. 
‘‘(B) CONSULTATION WITH OTHER AGEN-
CIES.—Before the submission of the National 
Drug Control Strategy or annual supplement 
required under section 1005(d), as applicable, 
the United States Interdiction Coordinator shall 
issue the National Interdiction Command and 
Control Plan, in consultation with the other 
members of the Interdiction Committee de-
scribed in subsection (b). 
‘‘(C) REPORT TO CONGRESS.—On or be-
fore September 1 of each year, the Director, 
through the United States Interdiction Coordi-
nator, shall provide to the appropriate congres-
sional committees, to the Committee on Armed 
Services and the Committee on Homeland Secu-
rity of the House of Representatives, and to the 
Committee on Homeland Security and Govern-
mental Affairs and the Committee on Armed 
Services of the Senate, a report that— 
‘‘(i) includes— 
‘‘(I) a copy of that year’s Na-
tional 
Interdiction 
Command 
and 
Control Plan; 
‘‘(II) information for the previous 
10 years regarding the number and 
type of seizures of drugs by each Na-
tional Drug Control Program Agency 
conducting drug interdiction activities 
and statistical information on the geo-
graphic areas of such seizures; and 
‘‘(III) information for the pre-
vious 10 years regarding the number 
of air and maritime patrol hours un-
dertaken by each National Drug Con-
trol Program Agency conducting drug 
interdiction activities and statistical 
information on the geographic areas
in which such patrol hours took place; 
and 
‘‘(ii) may include recommendations 
about changes to existing agency authori-
ties or laws governing interagency relation-
ships. 
‘‘(D) CLASSIFIED
ANNEX.—The report 
submitted pursuant to subparagraph (C) may 
include a classified annex. 
‘‘(b) INTERDICTION COMMITTEE.— 
‘‘(1) IN
GENERAL.—The Interdiction Com-
mittee shall meet to— 
‘‘(A) discuss and resolve issues related to 
the coordination, oversight, and integration of 
international, border, and domestic drug inter-
diction efforts in support of the National Drug 
Control Strategy; 
‘‘(B) review the annual National Interdic-
tion Command and Control Plan, and provide 
advice to the Director and the United States 
Interdiction Coordinator concerning that plan; 
and 
‘‘(C) provide such other advice to the Di-
rector concerning drug interdiction strategy and
policies as the committee determines is appro-
priate. 
‘‘(2) CHAIR.—The Director shall designate one 
of the members of the Interdiction Committee to 
serve as Chair. 
‘‘(3) MEETINGS.—The members of the Interdic-
tion Committee shall meet, in person and not 
through any delegate or representative, at least once 
per calendar year, before June 1. At the call of the 
Director or the Chair, the Interdiction Committee 
may hold additional meetings, which shall be at-
tended by the members in person, or through such 
delegates or representatives as the members may 
choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the Chair of the Interdiction Committee 
shall submit to the Director and to the appropriate 
congressional committees a report describing the re-
sults of the meetings and any significant findings of 
the committee during the previous 12 months. Such 
report may include a classified annex. 
‘‘§ 1012. Treatment coordinator 
‘‘(a) UNITED STATES TREATMENT COORDINATOR.— 
‘‘(1) IN
GENERAL.—The Director shall des-
ignate or appoint a noncareer appointee in the Sen-
ior Executive Service or a career appointee at the 
GS–15 level (or equivalent) or above as the United 
States Treatment Coordinator to perform the re-
sponsibilities of that position described in paragraph 
(2) and such other duties as may be determined by 
the Director with respect to coordination of efforts 
to expand the availability of substance use disorder 
treatment with the goal of eliminating the unmet 
treatment need. 
‘‘(2) RESPONSIBILITIES.—The United States 
Treatment Coordinator shall be responsible to the 
Director for— 
‘‘(A) coordinating the activities of the Na-
tional Drug Control Program Agencies under-
taken to expand the availability of evidence- 
based substance use disorder treatment to en-
sure consistency with the National Drug Con-
trol Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before September 1 of each 
year and in accordance with paragraph (4), a 
National Treatment Plan to ensure the coordi-
nation and consistency described in subpara-
graph (A);
‘‘(C) assessing the sufficiency of Federal 
resources directed to substance use disorder 
treatment by the relevant National Drug Con-
trol Program Agencies; 
‘‘(D) encouraging the adoption by all sub-
stance use disorder treatment providers of evi-
dence-based standards to guide all aspects of 
treatment provided; and 
‘‘(E) advising the Director on the efforts 
of each National Drug Control Program Agency 
to implement the National Treatment Plan. 
‘‘(3) STAFF.—The Director shall assign such 
permanent staff of the Office of the United States 
Treatment Coordinator as the Director determines 
to be appropriate to assist the United States Treat-
ment Coordinator to carry out the responsibilities 
described in paragraph (2), and may request that 
appropriate National Drug Control Program Agen-
cies detail or assign staff to assist in carrying out 
such responsibilities. 
‘‘(4) NATIONAL TREATMENT PLAN.— 
‘‘(A) PURPOSES.—The National Treatment 
Plan— 
‘‘(i) shall identify the unmet need for 
treatment for evidence-based substance use
disorders and set forth the Government’s 
strategy for closing the gap between avail-
able and needed treatment through all 
sources; 
‘‘(ii) shall describe the specific roles 
and responsibilities of the relevant Na-
tional Drug Control Program Agencies for 
implementing that strategy; 
‘‘(iii) shall identify the specific re-
sources required to enable the relevant Na-
tional Drug Control Program Agencies to 
implement that strategy; 
‘‘(iv) shall identify the resources, in-
cluding private sources, required to elimi-
nate the unmet need for evidence-based 
substance use disorder treatment; and 
‘‘(v) may include recommendations 
about changes to existing agency authori-
ties or laws governing interagency relation-
ships. 
‘‘(B) CONSULTATION WITH OTHER AGEN-
CIES.—Before the submission of the National 
Treatment Strategy or annual supplement re-
quired under section 1005(d), as applicable, the 
United States Treatment Coordinator shall
issue the National Treatment Plan, in consulta-
tion with the other members of the Treatment 
Committee described in subsection (b). 
‘‘(C) REPORT TO CONGRESS.—On or be-
fore September 1 of each year, the Director, 
through the United States Treatment Coordi-
nator, shall provide to the appropriate congres-
sional committees a report that includes a copy 
of that year’s National Treatment Plan. 
‘‘(b) TREATMENT COMMITTEE.— 
‘‘(1) IN GENERAL.—The Treatment Committee 
shall meet to— 
‘‘(A) review and discuss the adequacy of 
evidence-based substance use disorder treat-
ment as well as the unmet need for treatment; 
‘‘(B) review and discuss the status of the 
implementation of the National Treatment 
Plan; and 
‘‘(C) provide such other advice to the Di-
rector concerning substance use disorder treat-
ment initiatives as the committee determines is 
appropriate. 
‘‘(2) CHAIR.—The Director shall designate one 
of the members of the Treatment Committee to 
serve as Chair.
‘‘(3) MEETINGS.—The members of the Treat-
ment Committee shall meet, in person and not 
through any delegate or representative, at least once 
per calendar year, before June 1. At the call of the 
Director or the Chair, the Treatment Committee 
may hold additional meetings, which shall be at-
tended by the members in person, or through such 
delegates or representatives as the members may 
choose. 
‘‘(4) REPORT.—Not later than September 30 of 
each year, the Chair of the Treatment Committee 
shall submit to the Director and to the appropriate 
congressional committees a report describing the re-
sults of the meetings and any significant findings of 
the committee during the previous 12 months. Such 
report may include a classified annex. 
‘‘§ 1013. Critical information coordination 
‘‘(a) NATIONAL DRUG CONTROL FUSION CENTER.— 
‘‘(1) ESTABLISHMENT.—The Director shall, in 
consultation with the head of each National Drug 
Control Program Agency, designate an agency to es-
tablish a National Drug Control Fusion Center (re-
ferred to in this section as the ‘Center’). The Center 
shall operate under the authority of the Director and 
shall work with the National Drug Control Program
Agencies to collect, compile, analyze, and facilitate 
the sharing of data on the use of illicit drugs, treat-
ment for substance use disorder, and interdiction of 
illicit drugs. The Center shall be considered a ‘statis-
tical agency or unit’, as that term is defined in sec-
tion 502 of the Confidential Information Protection 
and Statistical Efficiency Act of 2002 (44 U.S.C. 
3501 note) and shall have the necessary independ-
ence to ensure any data or information acquired by 
an agency under a pledge of confidentiality and for 
exclusively statistical purposes is used exclusively for 
statistical purposes. 
‘‘(2) CENTER DIRECTOR.—There shall be at the 
head of the Center a Center Director who shall be 
appointed by the Director from among individuals 
qualified and distinguished in data governance and 
statistical analysis. 
‘‘(3) DATA COMPILATION.—The Director, act-
ing through the Center Director, shall do the fol-
lowing: 
‘‘(A) Coordinate data collection activities 
among the National Drug Control Program 
Agencies. 
‘‘(B) Collect information not otherwise col-
lected by National Drug Control Program
Agencies as necessary to inform the National 
Drug Control Strategy. 
‘‘(C) Compile and analyze any data re-
quired to be collected under this chapter. 
‘‘(D) Disseminate technology, as appro-
priate, to States and local jurisdictions to en-
able or improve the collection of data on drug 
use, including the recordation of the occurrence 
of fatal and non-fatal drug overdoses. 
‘‘(E) Compile information collected by Na-
tional Drug Control Program Agencies on 
grants issued through any National Drug Con-
trol Program, including for any grant the fol-
lowing: 
‘‘(i) The recipient. 
‘‘(ii) The amount. 
‘‘(iii) The intended purpose. 
‘‘(iv) Any evidence of the efficacy of 
the outcomes achieved by the program 
funded through the grant. 
‘‘(v) Any assessments of how the 
grant met its intended purpose. 
‘‘(4) TOXICOLOGY SCREENING.—
‘‘(A) ESTABLISHMENT.—The Center Di-
rector may establish a toxicology screening pro-
gram that engages in— 
‘‘(i) secondary analysis of urine sam-
ples that would otherwise be discarded 
by— 
‘‘(I) hospitals and substance use 
disorder treatment programs; 
‘‘(II) correctional facilities, book-
ing sites, probation programs, drug 
courts, and related facilities; and 
‘‘(III) coroners and medical ex-
aminers; and 
‘‘(ii) analysis of other physical sam-
ples, as determined by the Center Director 
to be valuable for understanding the preva-
lence of any illicit drug. 
‘‘(B) DE-IDENTIFICATION
OF
INFORMA-
TION.—The Center Director shall ensure that 
no samples have any personally identifiable in-
formation prior to collection. 
‘‘(C) LIMITATION ON USE.—No data ob-
tained from analysis conducted under this para-
graph may be used as evidence in any pro-
ceeding.
100 
‘‘(D) STATE PROGRAM.—The Center Di-
rector may establish a program that enables 
States and local jurisdictions to submit up to 
20 urine samples per year for toxicology anal-
ysis for the purposes of identifying substances 
present in individuals who have suffered fatal 
drug overdoses. 
‘‘(5) AUTHORITY TO CONTRACT.—The Director 
may award contracts, enter into interagency agree-
ments, manage individual projects, and conduct 
other operational activities under this subsection. 
‘‘(b) CRITICAL DRUG CONTROL INFORMATION AND 
EVIDENCE PLAN.— 
‘‘(1) IN
GENERAL.—Not later than the first 
Monday in February of each year, the Director shall 
submit to Congress a systematic plan for increasing 
data collection to enable real-time surveillance of 
drug control threats, developing analysis and moni-
toring capabilities, and identifying and addressing 
policy questions relevant to the National Drug Con-
trol Policy, Strategy, and Program. Such plan shall 
be made available on the public online portal of the 
Office, shall cover at least a 4-year period beginning 
with the first fiscal year following the fiscal year in
101 
which the plan is submitted and published, and con-
tain the following: 
‘‘(A) A list of policy-relevant questions for 
which the Director and each National Drug 
Control Program Agency intends to develop evi-
dence to support the National Drug Control 
Program and Strategy. 
‘‘(B) A list of data the Director and each 
National Drug Control Program Agency intends 
to collect, use, or acquire to facilitate the use of 
evidence in drug control policymaking and mon-
itoring. 
‘‘(C) A list of methods and analytical ap-
proaches that may be used to develop evidence 
to support the National Drug Control Program 
and Strategy and related policy. 
‘‘(D) A list of any challenges to developing 
evidence to support policymaking, including any 
barriers to accessing, collecting, or using rel-
evant data. 
‘‘(E) A description of the steps the Direc-
tor and the head of each National Drug Control 
Program Agency will take to effectuate the 
plan.
102 
‘‘(F) Any other relevant information as de-
termined by the Director. 
‘‘(2) CONSULTATION.—In developing the plan 
required under paragraph (1), the Director shall 
consult with the following: 
‘‘(A) The public. 
‘‘(B) Any evaluation or analysis units and 
personnel of the Office. 
‘‘(C) Office officials responsible for imple-
menting privacy policy. 
‘‘(D) Office officials responsible for data 
governance. 
‘‘(E) The appropriate congressional com-
mittees. 
‘‘(F) Any other individual or entity as de-
termined by the Director. 
‘‘(c) EVIDENCE-BASED POLICY.— 
‘‘(1) HARM REDUCTION PROGRAMS.—When de-
veloping the national drug control policy, any policy 
of the Director, including policies relating to syringe 
exchange programs for intravenous drug users, shall 
be based on the best available medical and scientific 
evidence regarding the effectiveness of such policy in 
promoting individual health, preventing the spread 
of infectious disease and the impact of such policy
103 
on drug addiction and use. In making any policy re-
lating to harm reduction programs, the Director 
shall consult with the National Institutes of Health 
and the National Academy of Sciences. 
‘‘(2) FUND RESTRICTION FOR THE LEGALIZA-
TION OF CONTROLLED SUBSTANCES.—The Director 
shall ensure that no Federal funds appropriated to 
the Office shall be expended for any study or con-
tract relating to the legalization (for a medical use 
or any other use) for which a listing in schedule I 
is in effect under section 202 of the Controlled Sub-
stances Act (21 U.S.C. 812). 
‘‘(d) DRUG CONTROL DATA DASHBOARD.— 
‘‘(1) ESTABLISHMENT.—The Director, in con-
sultation with the Center Director, shall establish 
and maintain a data dashboard on the online portal 
of the Office to be known as the ‘Drug Control Data 
Dashboard’. The Director shall ensure the user 
interface of the dashboard is constructed with mod-
ern design standards. To the extent practicable, the 
data made available on the dashboard shall be pub-
licly available in a machine-readable format and 
searchable by year, agency, drug, and location. 
‘‘(2) DATA.—The data included in the Drug 
Control Data Dashboard shall be updated quarterly
104 
to the extent practicable, but not less frequently 
than annually and shall include, at a minimum, the 
following: 
‘‘(A) For each substance identified under 
section 1005(c)(1)(A)(i)— 
‘‘(i) the total amount seized and dis-
rupted in the calendar year and each of 
the previous 3 calendar years, including to 
the extent practicable the amount seized by 
State, local, and Tribal governments; 
‘‘(ii) the known and estimated flows 
into the United States from all sources in 
the calendar year and each of the previous 
3 calendar years; 
‘‘(iii) the total amount of known flows 
that could not be interdicted or disrupted 
in the calendar year and each of the pre-
vious 3 calendar years; 
‘‘(iv) the known and estimated levels 
of domestic production in the calendar year 
and each of the previous 3 calendar years, 
including the levels of domestic production 
if the drug is a prescription drug, as deter-
mined under the Federal Food, Drug, and 
Cosmetic Act, for which a listing is in ef-
105 
fect under section 202 of the Controlled 
Substances Act (21 U.S.C. 812); 
‘‘(v) the average street price for the 
calendar year and the highest known street 
price during the preceding 10-year period; 
and 
‘‘(vi) to the extent practicable, related 
prosecutions by State, local, and Tribal 
governments. 
‘‘(B) For the calendar year and each of the 
previous 3 years data sufficient to show, 
disaggregated by State and, to the extent fea-
sible, by region within a State, county, or city, 
the following: 
‘‘(i) The number of fatal and non- 
fatal overdoses caused by each drug identi-
fied under subparagraph (A)(i). 
‘‘(ii) The prevalence of substance use 
disorders. 
‘‘(iii) The number of individuals who 
have received substance use disorder treat-
ment, including medication assisted treat-
ment, for a substance use disorder, includ-
ing treatment provided through publicly-fi-
nanced health care programs.
106 
‘‘(iv) The extent of the unmet need 
for substance use disorder treatment, in-
cluding the unmet need for medication-as-
sisted treatment. 
‘‘(C) Data sufficient to show the extent of 
prescription drug diversion, trafficking, and 
misuse in the calendar year and each of the 
previous 3 calendar years. 
‘‘(D) Any quantifiable measures the Direc-
tor determines to be appropriate to detail 
progress toward the achievement of the goals of 
the National Drug Control Strategy. 
‘‘(e) ACCESS TO INFORMATION.— 
‘‘(1) IN GENERAL.—Upon the request of the 
Director, the head of any National Drug Control 
Program Agency shall cooperate with and provide to 
the Director any statistics, studies, reports, and 
other information prepared or collected by the agen-
cy concerning the responsibilities of the agency 
under the National Drug Control Strategy that re-
late to— 
‘‘(A) drug control; or 
‘‘(B) the manner in which amounts made 
available to that agency for drug control are 
being used by that agency.
107 
‘‘(2) PROTECTION OF INTELLIGENCE INFORMA-
TION.— 
‘‘(A) IN GENERAL.—The authorities con-
ferred on the Office and the Director by this 
chapter shall be exercised in a manner con-
sistent with provisions of the National Security 
Act of 1947 (50 U.S.C. 401 et seq.). The Di-
rector of National Intelligence shall prescribe 
such regulations as may be necessary to protect 
information provided pursuant to this chapter 
regarding intelligence sources and methods. 
‘‘(B) DUTIES OF DIRECTOR.—The Director 
of National Intelligence and the Director of the 
Central Intelligence Agency shall, to the max-
imum extent practicable in accordance with 
subparagraph (A), render full assistance and 
support to the Office and the Director. 
‘‘(3) REQUIRED
REPORTS
FROM
NATIONAL 
DRUG CONTROL PROGRAM AGENCIES.—The head of 
each National Drug Control Program Agency shall 
submit to the Director such information and reports 
as requested from such National Drug Control Pro-
gram Agency by the Director, which shall include 
from the appropriate National Drug Control Pro-
gram Agencies:
108 
‘‘(A) Not later than July 1 of each year, 
the head of a National Drug Control Program 
Agency designated by the Director shall submit 
to the Director and the appropriate congres-
sional committees an assessment of the quantity 
of illegal drug cultivation and manufacturing in 
the United States on lands owned or under the 
jurisdiction of their respective agencies that was 
seized or eradicated by their personnel during 
the preceding calendar year. 
‘‘(B) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding— 
‘‘(i) the number and type of seizures 
of drugs by each component of the agency 
seizing drugs, as well as statistical infor-
mation on the geographic areas of such 
seizures; and 
‘‘(ii) the number of air and maritime 
patrol hours primarily dedicated to drug 
supply reduction missions undertaken by 
each component of the agency.
109 
‘‘(C) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding 
the number of air and maritime patrol hours 
primarily dedicated to drug supply reduction 
missions undertaken by each component of the 
agency. 
‘‘(D) Not later than July 1 of each year, 
the head of a designated National Drug Control 
Program Agency shall submit to the Director 
and the appropriate congressional committees 
information for the preceding year regarding 
the number and type of— 
‘‘(i) arrests for drug violations; 
‘‘(ii) prosecutions by United States 
Attorneys for drug violations; and 
‘‘(iii) seizures of drugs by each com-
ponent of the Department of Justice seiz-
ing drugs, as well as statistical information 
on the geographic areas of such seizures. 
‘‘(f) DATA EXCHANGE STANDARDS FOR IMPROVED 
INTEROPERABILITY.—
110 
‘‘(1) INTERAGENCY AND INTERGOVERNMENTAL 
DESIGNATION AND USE OF DATA EXCHANGE STAND-
ARDS WORKING GROUP.—The Director shall estab-
lish a working group of National Drug Control Pro-
gram Agencies, State, local and Tribal government 
health and law enforcement agencies, and data gov-
ernance experts to develop consensus data exchange 
standards for necessary categories of information 
that allow effective electronic exchange of informa-
tion between States, between State agencies, be-
tween States and National Drug Control Program 
Agencies, and any other drug control relevant data 
exchange. 
‘‘(2) DATA
EXCHANGE
STANDARDS
MUST
BE 
NONPROPRIETARY AND INTEROPERABLE.—The data 
exchange standards developed under paragraph (1) 
shall, to the extent practicable, be nonproprietary 
and interoperable. 
‘‘(3) OTHER
REQUIREMENTS.—In developing 
data exchange standards under this subsection, the 
working group shall, to the extent practicable, incor-
porate— 
‘‘(A) interoperable standards developed 
and maintained by an international voluntary
111 
consensus standards body, as defined by the Of-
fice of Management and Budget; 
‘‘(B) interoperable standards developed 
and maintained by intergovernmental partner-
ships; and 
‘‘(C) interoperable standards developed 
and maintained by Federal entities with author-
ity over contracting and financial assistance. 
‘‘(4) DATA EXCHANGE STANDARDS FOR FED-
ERAL REPORTING.— 
‘‘(A) DESIGNATION.—The Director may, in 
consultation with the working group established 
under this subsection, National Drug Control 
Program Agencies, and State, local, and Tribal 
governments, designate data exchange stand-
ards to govern Federal reporting and exchange 
requirements for National Drug Control Pro-
grams, as appropriate. 
‘‘(B) REQUIREMENTS.—The data exchange 
reporting standards designated under subpara-
graph (A) shall, to the extent practicable— 
‘‘(i) incorporate a widely accepted, 
nonproprietary, searchable, machine-read-
able format;
112 
‘‘(ii) be consistent with and implement 
applicable accounting principles; 
‘‘(iii) be implemented in a manner 
that is cost-effective and improves program 
efficiency and effectiveness; and 
‘‘(iv) be capable of being continually 
upgraded as necessary. 
‘‘(C) 
INCORPORATION
OF
NONPROPRI-
ETARY
STANDARDS.—In designating data ex-
change standards under this paragraph, the Di-
rector shall, to the extent practicable, incor-
porate existing nonproprietary standards. 
‘‘(D) RULE OF CONSTRUCTION.—Nothing 
in this paragraph shall be construed to require 
a change to existing data exchange standards 
for Federal reporting about a program referred 
to in this section, if the head of the agency re-
sponsible for administering the program finds 
the standards to be effective and efficient. 
‘‘(5) TERMINATION.—The working group estab-
lished under paragraph (1) shall terminate not ear-
lier than 60 days after the public notification of ter-
mination by the Director. 
‘‘(g) ANNUAL DATA COLLECTION AND DISSEMINA-
TION REQUIREMENTS.—
113 
‘‘(1) IN GENERAL.—The Director shall collect 
and disseminate, as appropriate, such information as 
the Director determines is appropriate, but not less 
than the information described in this subsection. To 
the extent practicable, the data shall be publicly 
available in a machine-readable format on the Drug 
Control Data Dashboard, be searchable by year, 
agency, drug, and location, and cover not less than 
the previous 10-year period. 
‘‘(2) PREPARATION AND DISSEMINATION OF IN-
FORMATION.—The Director shall prepare and dis-
seminate the following: 
‘‘(A) An assessment of current illicit drug 
use (including inhalants and steroids) and avail-
ability, impact of illicit drug use, and treatment 
availability, which assessment shall include— 
‘‘(i) estimates of drug prevalence and 
frequency of use as measured by national, 
State, and local surveys of illicit drug use 
and by other special studies of non-
dependent and dependent illicit drug use; 
‘‘(ii) illicit drug use in the workplace 
and the productivity lost by such use; and 
‘‘(iii) illicit drug use by arrestees, pro-
bationers, and parolees.
114 
‘‘(B) An assessment of the reduction of il-
licit drug availability, for each drug identified 
under section 1005(c)(1)(A)(i), as measured 
by— 
‘‘(i) the quantities of such drug avail-
able for consumption in the United States; 
‘‘(ii) the amount of such drug enter-
ing the United States; 
‘‘(iii) the number of illicit drug manu-
facturing laboratories seized and destroyed 
of each such drug and the number of hec-
tares cultivated and destroyed domestically 
and in other countries of such drug; 
‘‘(iv) the number of metric tons of 
such drug seized; and 
‘‘(v) changes in the price and purity 
of such drug. 
‘‘(C) An assessment of the reduction of the 
consequences of illicit drug use and availability, 
which shall include— 
‘‘(i) the cost of treating substance use 
disorder in the United States, such as the 
quantity of illicit drug-related services pro-
vided;
115 
‘‘(ii) the annual national health care 
cost of illicit drug use; and 
‘‘(iii) the extent of illicit drug-related 
crime and criminal activity. 
‘‘(D) A determination of the status of sub-
stance use disorder treatment in the United 
States, by assessing— 
‘‘(i) public and private treatment utili-
zation; and 
‘‘(ii) the number of illicit drug users 
the Director estimates meet diagnostic cri-
teria for treatment. 
‘‘§ 1014. Authorization of appropriations 
‘‘There are authorized to be appropriated to carry out 
this chapter, except as otherwise specified, to remain avail-
able until expended, $18.4 million for each of fiscal years 
2019 through 2023. 
‘‘SUBCHAPTER II—DRUG-FREE COMMUNITIES 
SUPPORT PROGRAM 
‘‘§ 1021. Establishment of drug-free communities sup-
port program 
‘‘(a) ESTABLISHMENT.—The Director shall establish 
a program to support communities in the development and 
implementation of comprehensive, long-term plans and
116 
programs to prevent and treat substance use and misuse 
among youth. 
‘‘(b) PROGRAM.—In carrying out the Program, the 
Director shall— 
‘‘(1) make and track grants to grant recipients; 
‘‘(2) provide for technical assistance and train-
ing, data collection, and dissemination of informa-
tion on state-of-the-art practices that the Director 
determines to be effective in reducing substance use; 
and 
‘‘(3) provide for the general administration of 
the Program. 
‘‘(c) ADMINISTRATION.—The Director shall appoint 
an Administrator to carry out the Program. 
‘‘(d) CONTRACTING.—The Director may employ any 
necessary staff and may enter into contracts or agree-
ments with National Drug Control Program Agencies, in-
cluding interagency agreements, to delegate authority for 
the execution of grants and for such other activities nec-
essary to carry out this chapter. 
‘‘§ 1022. Program authorization 
‘‘(a) GRANT ELIGIBILITY.—To be eligible to receive 
an initial grant or a renewal grant under this subchapter, 
a coalition shall meet each of the following criteria:
117 
‘‘(1) APPLICATION.—The coalition shall submit 
an application to the Administrator in accordance 
with section 1023(a)(2). 
‘‘(2) MAJOR SECTOR INVOLVEMENT.— 
‘‘(A) IN
GENERAL.—The coalition shall 
consist of one or more representatives of each 
of the following categories: 
‘‘(i) Youth. 
‘‘(ii) Parents. 
‘‘(iii) Businesses. 
‘‘(iv) The media. 
‘‘(v) Schools. 
‘‘(vi) Organizations serving youth. 
‘‘(vii) Law enforcement. 
‘‘(viii) Religious or fraternal organiza-
tions. 
‘‘(ix) Civic and volunteer groups. 
‘‘(x) Health care professionals. 
‘‘(xi) State, local, or Tribal govern-
mental agencies with expertise in the field 
of substance use prevention or substance 
use disorders (including, if applicable, the 
State authority with primary authority for 
substance use and misuse).
118 
‘‘(xii) Other organizations involved in 
reducing the prevalence of substance use 
and misuse or substance use disorders. 
‘‘(B) ELECTED OFFICIALS.—If feasible, in 
addition to representatives from the categories 
listed in subparagraph (A), the coalition shall 
have an elected official (or a representative of 
an elected official) from— 
‘‘(i) the Federal Government; and 
‘‘(ii) the government of the appro-
priate State and political subdivision there-
of or the governing body or an Indian tribe 
(as that term is defined in section 4(e) of 
the Indian Self-Determination Act (25 
U.S.C. 5304)). 
‘‘(C) 
REPRESENTATION.—An 
individual 
who is a member of the coalition may serve on 
the coalition as a representative of not more 
than one category listed under subparagraph 
(A). 
‘‘(3) COMMITMENT.—The coalition shall dem-
onstrate, to the satisfaction of the Administrator— 
‘‘(A) that the representatives of the coali-
tion have worked together on substance use and 
misuse reduction initiatives, which, at a min-
119 
imum, includes initiatives that target drugs de-
scribed in section 1027(6)(A), for a period of 
not less than 6 months, acting through entities 
such as task forces, subcommittees, or commu-
nity boards; and 
‘‘(B) substantial participation from volun-
teer leaders in the community involved (espe-
cially in cooperation with individuals involved 
with youth such as parents, teachers, coaches, 
youth workers, and members of the clergy). 
‘‘(4) MISSION AND STRATEGIES.—The coalition 
shall, with respect to the community involved— 
‘‘(A) have as its principal mission the re-
duction of illegal drug use, which, at a min-
imum, includes the use of illegal drugs de-
scribed in section 1027(6)(A), in a comprehen-
sive and long-term manner, with a primary 
focus on youth in the community; 
‘‘(B) describe and document the nature 
and extent of the substance use and misuse 
problem, which, at a minimum, includes the use 
and misuse of drugs described in section 
1027(6)(A), in the community; 
‘‘(C)(i) provide a description of substance 
use and misuse prevention and treatment pro-
120 
grams and activities, which, at a minimum, in-
cludes programs and activities relating to the 
use and misuse of drugs described in section 
1027(6)(A), in existence at the time of the 
grant application; and 
‘‘(ii) identify substance use and misuse 
programs and service gaps, which, at a min-
imum, includes programs and gaps relating to 
the use and misuse of drugs described in sec-
tion 1027(6)(A), in the community; 
‘‘(D) develop a strategic plan to reduce 
substance use and misuse among youth, which, 
at a minimum, includes the use and misuse of 
drugs described in section 1027(6)(A), in a 
comprehensive and long-term fashion; and 
‘‘(E) work to develop a consensus regard-
ing the priorities of the community to combat 
substance use and misuse among youth, which, 
at a minimum, includes the use and misuse of 
drugs described in section 1027(6)(A). 
‘‘(5) SUSTAINABILITY.—The coalition shall 
demonstrate that the coalition is an ongoing concern 
by demonstrating that the coalition— 
‘‘(A) is— 
‘‘(i)(I) a nonprofit organization; or
121 
‘‘(II) an entity that the Administrator 
determines to be appropriate; or 
‘‘(ii) part of, or is associated with, an 
established legal entity; 
‘‘(B) receives financial support (including, 
in the discretion of the Administrator, in-kind 
contributions) from non-Federal sources; and 
‘‘(C) has a strategy to solicit substantial fi-
nancial support from non-Federal sources to en-
sure that the coalition and the programs oper-
ated by the coalition are self-sustaining. 
‘‘(6) ACCOUNTABILITY.—The coalition shall— 
‘‘(A) establish a system to measure and re-
port outcomes— 
‘‘(i) consistent with common indica-
tors and evaluation protocols established 
by the Administrator; and 
‘‘(ii) approved by the Administrator; 
‘‘(B) conduct— 
‘‘(i) for an initial grant under this 
subchapter, an initial benchmark survey of 
drug use among youth (or use local sur-
veys or performance measures available or 
accessible in the community at the time of 
the grant application); and
122 
‘‘(ii) biennial surveys (or incorporate 
local surveys in existence at the time of the 
evaluation) to measure the progress and 
effectiveness of the coalition; and 
‘‘(C) provide assurances that the entity 
conducting an evaluation under this paragraph, 
or from which the coalition receives informa-
tion, has experience— 
‘‘(i) in gathering data related to sub-
stance use and misuse among youth; or 
‘‘(ii) in evaluating the effectiveness of 
community anti-drug coalitions. 
‘‘(7) ADDITIONAL
CRITERIA.—The Director 
shall not impose any eligibility criteria on new appli-
cants or renewal grantees not provided in this chap-
ter. 
‘‘(b) GRANT AMOUNTS.— 
‘‘(1) IN GENERAL.— 
‘‘(A) GRANTS.— 
‘‘(i) IN GENERAL.—Subject to clause 
(iv), for a fiscal year, the Administrator 
may grant to an eligible coalition under 
this paragraph, an amount not to exceed 
the amount of non-Federal funds raised by
123 
the coalition, including in-kind contribu-
tions, for that fiscal year. 
‘‘(ii) SUSPENSION
OF
GRANTS.—If 
such grant recipient fails to continue to 
meet the criteria specified in subsection 
(a), the Administrator may suspend the 
grant, after providing written notice to the 
grant recipient and an opportunity to ap-
peal. 
‘‘(iii) RENEWAL GRANTS.—Subject to 
clause (iv), the Administrator may award a 
renewal grant to a grant recipient under 
this subparagraph for each fiscal year fol-
lowing the fiscal year for which an initial 
grant is awarded, in an amount not to ex-
ceed the amount of non-Federal funds 
raised by the coalition, including in-kind 
contributions, for that fiscal year, during 
the 4-year period following the period of 
the initial grant. 
‘‘(iv) LIMITATION.—The amount of a 
grant award under this subparagraph may 
not exceed $125,000 for a fiscal year. 
‘‘(B) COALITION AWARDS.—
124 
‘‘(i) IN
GENERAL.—Except as pro-
vided in clause (ii), the Administrator may, 
with respect to a community, make a grant 
to one eligible coalition that represents 
that community. 
‘‘(ii) EXCEPTION.—The Administrator 
may make a grant to more than one eligi-
ble coalition that represents a community 
if— 
‘‘(I) the eligible coalitions dem-
onstrate that the coalitions are col-
laborating with one another; and 
‘‘(II) each of the coalitions has 
independently met the requirements 
set forth in subsection (a). 
‘‘(2) RURAL COALITION GRANTS.— 
‘‘(A) IN GENERAL.— 
‘‘(i) IN
GENERAL.—In addition to 
awarding grants under paragraph (1), to 
stimulate the development of coalitions in 
sparsely populated and rural areas, the 
Administrator may award a grant in ac-
cordance with this section to a coalition 
that represents a county with a population 
that does not exceed 30,000 individuals. In
126 
cal year for which an initial grant is awarded, 
in an amount not to exceed the amount of non- 
Federal funds raised by the coalition, including 
in-kind contributions, during the 4-year period 
following the period of the initial grant. 
‘‘(C) LIMITATIONS.— 
‘‘(i) AMOUNT.—The amount of a 
grant award under this paragraph shall 
not exceed $125,000 for a fiscal year. 
‘‘(ii) AWARDS.—With respect to a 
county referred to in subparagraph (A), 
the Administrator may award a grant 
under this section to not more than one el-
igible coalition that represents the county. 
‘‘(3) ADDITIONAL GRANTS.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (F), the Administrator may award an ad-
ditional grant under this paragraph to an eligi-
ble coalition awarded a grant under paragraph 
(1) or (2) for any first fiscal year after the end 
of the 4-year period following the period of the 
initial grant under paragraph (1) or (2), as the 
case may be. 
‘‘(B) SCOPE
OF
GRANTS.—A coalition 
awarded a grant under paragraph (1) or (2),
127 
including a renewal grant under such para-
graph, may not be awarded another grant 
under such paragraph, and is eligible for an ad-
ditional grant under this section only under this 
paragraph. 
‘‘(C) NO PRIORITY FOR APPLICATIONS.— 
The Administrator may not afford a higher pri-
ority in the award of an additional grant under 
this paragraph than the Administrator would 
afford the applicant for the grant if the appli-
cant were submitting an application for an ini-
tial grant under paragraph (1) or (2) rather 
than an application for a grant under this para-
graph. 
‘‘(D) RENEWAL GRANTS.—Subject to sub-
paragraph (F), the Administrator may award a 
renewal grant to a grant recipient under this 
paragraph for each of the fiscal years of the 4- 
fiscal-year period following the fiscal year for 
which the initial additional grant under sub-
paragraph (A) is awarded in an amount not to 
exceed amounts as follows: 
‘‘(i) For the first and second fiscal 
years of that 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
128 
ing in-kind contributions, raised by the co-
alition for the applicable fiscal year is not 
less than 125 percent of the amount 
awarded. 
‘‘(ii) For the third and fourth fiscal 
years of that 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
ing in-kind contributions, raised by the co-
alition for the applicable fiscal year is not 
less than 150 percent of the amount 
awarded. 
‘‘(E) SUSPENSION.—If a grant recipient 
under this paragraph fails to continue to meet 
the criteria specified in subsection (a), the Ad-
ministrator may suspend the grant, after pro-
viding written notice to the grant recipient and 
an opportunity to appeal. 
‘‘(F) LIMITATION.—The amount of a grant 
award under this paragraph may not exceed 
$125,000 for a fiscal year. 
‘‘(4) PROCESS
FOR
SUSPENSION.—A grantee 
shall not be suspended or terminated under para-
graph (1)(A)(ii), (2)(A)(iii), or (3)(E) unless that 
grantee is afforded a fair, timely, and independent 
appeal prior to such suspension or termination.
129 
‘‘(c) TREATMENT OF FUNDS FOR COALITIONS REP-
RESENTING CERTAIN ORGANIZATIONS.—Funds appro-
priated for the substance use and misuse activities of a 
coalition that includes a representative of the Bureau of 
Indian Affairs, the Indian Health Service, or a Tribal gov-
ernment agency with expertise in the field of substance 
use prevention may be counted as non-Federal funds 
raised by the coalition for purposes of this section. 
‘‘(d) PRIORITY IN AWARDING GRANTS.—In awarding 
grants under subsection (b)(1)(A)(i), priority shall be 
given to a coalition serving economically disadvantaged 
areas. 
‘‘§ 1023. Information collection and dissemination 
with respect to grant recipients 
‘‘(a) COALITION INFORMATION.— 
‘‘(1) GENERAL AUDITING AUTHORITY.—For the 
purpose of audit and examination, the Adminis-
trator— 
‘‘(A) shall have access to any books, docu-
ments, papers, and records that are pertinent to 
any grant or grant renewal request under this 
subchapter; and 
‘‘(B) may periodically request information 
from a grant recipient to ensure that the grant
130 
recipient meets the applicable criteria under 
section 1022(a). 
‘‘(2) APPLICATION
PROCESS.—The Adminis-
trator shall issue a request for proposal regarding, 
with respect to the grants awarded under section 
1022, the application process, grant renewal, and 
suspension or withholding of renewal grants. Each 
application under this paragraph shall be in writing 
and shall be subject to review by the Administrator. 
‘‘(3) REPORTING.—The Administrator shall, to 
the maximum extent practicable and in a manner 
consistent with applicable law, minimize reporting 
requirements by a grant recipient and expedite any 
application for a renewal grant made under this sub-
chapter. 
‘‘(b) DATA COLLECTION AND DISSEMINATION.— 
‘‘(1) IN
GENERAL.—The Administrator may 
collect data from— 
‘‘(A) national substance use and misuse or-
ganizations that work with eligible coalitions, 
community anti-drug coalitions, departments or 
agencies of the Federal Government, or State 
or local governments and the governing bodies 
of Indian Tribes; and
131 
‘‘(B) any other entity or organization that 
carries out activities that relate to the purposes 
of the Program. 
‘‘(2) ACTIVITIES OF ADMINISTRATOR.—The Ad-
ministrator may— 
‘‘(A) evaluate the utility of specific initia-
tives relating to the purposes of the Program; 
‘‘(B) conduct an evaluation of the Pro-
gram; and 
‘‘(C) disseminate information described in 
this subsection to— 
‘‘(i) eligible coalitions and other sub-
stance use prevention organizations; and 
‘‘(ii) the general public. 
‘‘(3) CONSULTATION.—The Administrator shall 
carry out activities under this subsection in consulta-
tion with the National Community Antidrug Coali-
tion Institute. 
‘‘(4) LIMITATION ON USE OF CERTAIN FUNDS 
FOR EVALUATION OF PROGRAM.—Amounts for ac-
tivities under paragraph (2)(B) may not be derived 
from amounts under section 1028(a) except for 
amounts that are available under section 1028(b) for 
administrative costs.
132 
‘‘§ 1024. Technical assistance and training 
‘‘(a) IN GENERAL.— 
‘‘(1) TECHNICAL
ASSISTANCE
AND
AGREE-
MENTS.—With respect to any grant recipient or 
other organization, the Administrator may— 
‘‘(A) offer technical assistance and train-
ing; and 
‘‘(B) enter into contracts and cooperative 
agreements. 
‘‘(2) COORDINATION OF PROGRAMS.—The Ad-
ministrator may facilitate the coordination of pro-
grams between a grant recipient and other organiza-
tions and entities. 
‘‘(b) TRAINING.—The Administrator may provide 
training to any representative designated by a grant re-
cipient in— 
‘‘(1) coalition building; 
‘‘(2) task force development; 
‘‘(3) mediation and facilitation, direct service, 
assessment and evaluation; or 
‘‘(4) any other activity related to the purposes 
of the Program. 
‘‘§ 1025. Supplemental grants for coalition mentoring 
activities 
‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 
Program, the Director may award an initial grant under
135 
‘‘(1) continues to meet the criteria specified in 
subsection (d); and 
‘‘(2) has made demonstrable progress in the de-
velopment of one or more new, self-supporting com-
munity coalitions that are focused on the prevention 
and treatment of substance use and misuse. 
‘‘(g) GRANT AMOUNTS.— 
‘‘(1) IN GENERAL.—Subject to paragraphs (2) 
and (3), the total amount of grants awarded to a co-
alition under this section for a fiscal year may not 
exceed the amount of non-Federal funds raised by 
the coalition, including in-kind contributions, for 
that fiscal year. Funds appropriated for the sub-
stance use and misuse activities of a coalition that 
includes a representative of the Bureau of Indian 
Affairs, the Indian Health Service, or a Tribal gov-
ernment agency with expertise in the field of sub-
stance use prevention may be counted as non-Fed-
eral funds raised by the coalition. 
‘‘(2) INITIAL GRANTS.—The amount of the ini-
tial grant awarded to a coalition under subsection 
(a) may not exceed $75,000. 
‘‘(3) RENEWAL GRANTS.—The total amount of 
renewal grants awarded to a coalition under sub-
136 
section (f) for any fiscal year may not exceed 
$75,000. 
‘‘(h) FISCAL YEAR LIMITATION ON AMOUNT AVAIL-
ABLE
FOR GRANTS.—The total amount available for 
grants under this section, including renewal grants under 
subsection (f), in any fiscal year may not exceed the 
amount equal to 5 percent of the amount authorized to 
be appropriated by section 1028 for that fiscal year. 
‘‘(i) PRIORITY IN AWARDING INITIAL GRANTS.—In 
awarding initial grants under this section, priority shall 
be given to a coalition that expressly proposes to provide 
mentorship to a coalition or aspiring coalition serving eco-
nomically disadvantaged areas. 
‘‘§ 1026. Authorization for National Community Anti-
drug Coalition Institute 
‘‘(a) IN
GENERAL.—The Director shall, using 
amounts authorized to be appropriated by subsection (d), 
make a competitive grant to provide for the continuation 
of the National Community Anti-drug Coalition Institute. 
‘‘(b) ELIGIBLE ORGANIZATIONS.—An organization 
eligible for the grant under subsection (a) is any national 
nonprofit organization that represents, provides technical 
assistance and training to, and has special expertise and 
broad, national-level experience in community antidrug 
coalitions under this subchapter.
137 
‘‘(c) USE OF GRANT AMOUNT.—The organization 
that receives the grant under subsection (a) shall continue 
a National Community Anti-Drug Coalition Institute to— 
‘‘(1) provide education, training, and technical 
assistance for coalition leaders and community 
teams, with emphasis on the development of coali-
tions serving economically disadvantaged areas; 
‘‘(2) develop and disseminate evaluation tools, 
mechanisms, and measures to better assess and doc-
ument coalition performance measures and out-
comes; and 
‘‘(3) bridge the gap between research and prac-
tice by translating knowledge from research into 
practical information. 
‘‘(d) AUTHORIZATION
OF APPROPRIATIONS.—The 
Director shall, using amounts authorized to be appro-
priated by section 1028, make a grant of $2 million under 
subsection (a), for each of the fiscal years 2019 through 
2023. 
‘‘§ 1027. Definitions 
‘‘In this subchapter: 
‘‘(1) ADMINISTRATOR.—The term ‘Adminis-
trator’ means the Administrator appointed by the 
Director under section 1021(c).
138 
‘‘(2) COMMUNITY.—The term ‘community’ shall 
have the meaning provided that term by the Admin-
istrator. 
‘‘(3) ELIGIBLE COALITION.—The term ‘eligible 
coalition’ means a coalition that meets the applicable 
criteria under section 1022(a). 
‘‘(4) GRANT RECIPIENT.—The term ‘grant re-
cipient’ means the recipient of a grant award under 
section 1022. 
‘‘(5) PROGRAM.—The term ‘Program’ means 
the program established under section 1021(a). 
‘‘(6) SUBSTANCE USE AND MISUSE.—The term 
‘substance use and misuse’ means— 
‘‘(A) the illegal use or misuse of drugs, in-
cluding substances for which a listing is in ef-
fect under any of schedules I through V under 
section 202 of the Controlled Substances Act 
(21 U.S.C. 812); 
‘‘(B) the misuse of inhalants or over the 
counter drugs; or 
‘‘(C) the use of alcohol, tobacco, or other 
related product as such use is prohibited by 
State or local law. 
‘‘(7) YOUTH.—The term ‘youth’ shall have the 
meaning provided that term by the Administrator.
139 
‘‘§ 1028. Drug–free communities reauthorization 
‘‘(a) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to the Office to carry 
out this subchapter $99 million for each of the fiscal years 
2019 through 2023. 
‘‘(b) ADMINISTRATIVE COSTS.—Not more than 8 
percent of the funds appropriated for this subchapter may 
be used by the Office or, in the discretion of the Director, 
an agency delegated to carry out the program under sec-
tion 1021(d) to pay for administrative costs associated 
with carrying out the program.’’. 
(d) TECHNICAL AND CONFORMING AMENDMENT.— 
The table of chapters for subtitle I of title 31, United 
States Code, is amended by adding at the end the fol-
lowing new item: 
‘‘10. Office of National Drug Control ...................................................... 1001’’. 
SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PRO-
GRAM. 
(a) ESTABLISHMENT.— 
(1) IN GENERAL.—There is established in the 
Office a program to be known as the High Intensity 
Drug Trafficking Areas Program (in this section re-
ferred to as the ‘‘Program’’). 
(2) PURPOSE.—The purpose of the Program is 
to reduce drug trafficking and drug production in 
the United States by—
140 
(A) facilitating cooperation among Federal, 
State, local, and Tribal law enforcement agen-
cies to share information and implement coordi-
nated enforcement activities; 
(B) enhancing law enforcement intelligence 
sharing among Federal, State, local, and Tribal 
law enforcement agencies; 
(C) providing reliable law enforcement in-
telligence to law enforcement agencies needed to 
design effective enforcement strategies and op-
erations; and 
(D) supporting coordinated law enforce-
ment strategies which maximize use of available 
resources to reduce the supply of illegal drugs 
in designated areas and in the United States as 
a whole. 
(b) DESIGNATION.— 
(1) IN GENERAL.—The Director, in consulta-
tion with the Attorney General, the Secretary of the 
Treasury, the Secretary of Homeland Security, the 
head of each National Drug Control Program Agen-
cy, and the Governor of each applicable State, may 
designate any specified area of the United States as 
a high intensity drug trafficking area.
141 
(2) ACTIVITIES.—After making a designation 
under paragraph (1) and in order to provide Federal 
assistance to the area so designated, the Director 
may— 
(A) obligate such sums as are appropriated 
for the Program; 
(B) direct the temporary reassignment of 
Federal personnel to such area, subject to the 
approval of the head of the agency that employs 
such personnel; 
(C) take any other action authorized under 
this section or chapter 10 of title 31, United 
States Code, as added by section 2(c), to pro-
vide increased Federal assistance to those 
areas; and 
(D) coordinate activities under this section 
(specifically administrative, recordkeeping, and 
funds management activities) with State, local, 
and Tribal officials. 
(c) PETITIONS
FOR DESIGNATION.—The Director 
shall establish and maintain regulations under which a co-
alition of interested law enforcement agencies from an 
area may petition for designation as a high intensity drug 
trafficking area (in this section referred to as the 
‘‘HIDTA’’). Such regulations shall provide for a regular
142 
review by the Director of the petition, including a rec-
ommendation regarding the merit of the petition to the 
Director by a panel of qualified, independent experts. 
(d) FACTORS FOR CONSIDERATION.—In considering 
whether to designate an area under this section as a high 
intensity drug trafficking area, the Director shall consider, 
in addition to such other criteria as the Director considers 
to be appropriate, the extent to which— 
(1) the area is a significant center of illegal 
drug production, manufacturing, importation, or dis-
tribution; 
(2) State, local, and Tribal law enforcement 
agencies have committed resources to respond to the 
drug trafficking problem in the area, thereby indi-
cating a determination to respond aggressively to the 
problem; 
(3) drug-related activities in the area are hav-
ing a significant harmful impact in the area, and in 
other areas of the country; and 
(4) a significant increase in allocation of Fed-
eral resources is necessary to respond adequately to 
drug-related activities in the area. 
(e) ORGANIZATION OF HIGH INTENSITY DRUG TRAF-
FICKING AREAS.—
143 
(1) EXECUTIVE BOARD AND OFFICERS.—To be 
eligible for funds appropriated under this section, 
each high intensity drug trafficking area shall be 
governed by an Executive Board. The Executive 
Board shall designate a chairman, vice chairman, 
and any other officers to the Executive Board that 
it determines are necessary. 
(2) RESPONSIBILITIES.—The Executive Board 
of a high intensity drug trafficking area shall be re-
sponsible for— 
(A) providing direction and oversight in es-
tablishing and achieving the goals of the high 
intensity drug trafficking area; 
(B) managing the funds of the high inten-
sity drug trafficking area; 
(C) reviewing and approving all funding 
proposals consistent with the overall objective of 
the high intensity drug trafficking area; and 
(D) reviewing and approving all reports to 
the Director on the activities of the high inten-
sity drug trafficking area. 
(3) BOARD
REPRESENTATION.—None of the 
funds appropriated under this section may be ex-
pended for any high intensity drug trafficking area, 
or for a partnership or region of a high intensity
144 
drug trafficking area, if the Executive Board for 
such area, region, or partnership, does not apportion 
an equal number of votes between representatives of 
participating agencies and representatives of partici-
pating State, local, and Tribal agencies. Where it is 
impractical for an equal number of representatives 
of agencies and State, local, and Tribal agencies to 
attend a meeting of an Executive Board in person, 
the Executive Board may use a system of proxy 
votes or weighted votes to achieve the voting balance 
required by this paragraph. 
(4) NO AGENCY RELATIONSHIP.—The eligibility 
requirements of this section are intended to ensure 
the responsible use of Federal funds. Nothing in this 
section is intended to create an agency relationship 
between individual high intensity drug trafficking 
areas and the Federal Government. 
(f) USE OF FUNDS.—The Director shall ensure that 
not more than 5 percent of Federal funds appropriated 
for the Program are expended for substance use disorder 
treatment programs and not more than 5 percent of the 
Federal funds appropriated for the Program are expended 
for drug prevention programs. 
(g) COUNTERTERRORISM ACTIVITIES.—
145 
(1) ASSISTANCE
AUTHORIZED.—The Director 
may authorize use of resources available for the Pro-
gram to assist Federal, State, local, and Tribal law 
enforcement agencies in investigations and activities 
related to terrorism and prevention of terrorism, es-
pecially but not exclusively with respect to such in-
vestigations and activities that are also related to 
drug trafficking. 
(2) LIMITATION.—The Director shall ensure— 
(A) that assistance provided under para-
graph (1) remains incidental to the purpose of 
the Program to reduce drug availability and 
carry out drug-related law enforcement activi-
ties; and 
(B) that significant resources of the Pro-
gram are not redirected to activities exclusively 
related to terrorism, except on a temporary 
basis under extraordinary circumstances, as de-
termined by the Director. 
(h) ROLE OF DRUG ENFORCEMENT ADMINISTRA-
TION.—The Director, in consultation with the Attorney 
General, shall ensure that a representative of the Drug 
Enforcement Administration is included in the Intelligence 
Support Center for each high intensity drug trafficking 
area.
146 
(i) EMERGING THREAT RESPONSE FUND.— 
(1) IN GENERAL.—Subject to the availability of 
appropriations, the Director may expend up to 10 
percent of the amounts appropriated under this sec-
tion on a discretionary basis, in accordance with the 
criteria established under paragraph (2)— 
(A) to respond to any emerging drug traf-
ficking threat in an existing high intensity drug 
trafficking area; 
(B) to establish a new high intensity drug 
trafficking area; or 
(C) to expand an existing high intensity 
drug trafficking area. 
(2) CONSIDERATION OF IMPACT.—In allocating 
funds under this subsection, the Director shall con-
sider— 
(A) the impact of activities funded on re-
ducing overall drug traffic in the United States, 
or minimizing the probability that an emerging 
drug trafficking threat will spread to other 
areas of the United States; and 
(B) such other criteria as the Director con-
siders appropriate. 
(j) ANNUAL HIDTA PROGRAM BUDGET SUBMIS-
SIONS.—As part of the documentation that supports the
147 
President’s annual budget request for the Office, the Di-
rector shall submit to Congress a budget justification that 
includes— 
(1) the amount proposed for each HIDTA, con-
ditional upon a review by the Office of the request 
submitted by such HIDTA and the performance of 
such HIDTA, with supporting narrative descriptions 
and rationale for each request; 
(2) a detailed justification that explains— 
(A) the reasons for the proposed funding 
level and how such funding level was deter-
mined based on a current assessment of the 
drug trafficking threat in each high intensity 
drug trafficking area; 
(B) how such funding will ensure that the 
goals and objectives of each such area will be 
achieved; and 
(C) how such funding supports the Na-
tional Drug Control Strategy; and 
(3) the amount of HIDTA funds used to inves-
tigate and prosecute organizations and individuals 
trafficking in each major illicit drug, as identified by 
the Director, in the prior calendar year, and a de-
scription of how those funds were used.
148 
(k) HIDTA ANNUAL EVALUATION REPORT.—As 
part of each report submitted pursuant to section 1006(a) 
of title 31, United States Code, as added by section 2(c), 
the Director shall include, for each designated high inten-
sity drug trafficking area, a report that— 
(1) describes— 
(A) the specific purposes for the high in-
tensity drug trafficking area; and 
(B) the specific long-term and short-term 
goals and objectives for the high intensity drug 
trafficking area; 
(2) includes an evaluation of the performance of 
the high intensity drug trafficking area in accom-
plishing the specific long-term and short-term goals 
and objectives identified under subparagraph (1)(B); 
(3) assesses the number and operation of all 
federally funded drug enforcement task forces within 
such high intensity drug trafficking area; 
(4) describes— 
(A) each Federal, State, local, and Tribal 
drug enforcement task force operating in such 
high intensity drug trafficking area; 
(B) how such task forces coordinate with 
each other, with any high intensity drug traf-
ficking area task force, and with investigations
149 
receiving funds from the Organized Crime and 
Drug Enforcement Task Force; 
(C) what steps, if any, each such task 
force takes to share information regarding drug 
trafficking and drug production with other fed-
erally funded drug enforcement task forces in 
the high intensity drug trafficking area; 
(D) the role of the high intensity drug 
trafficking area in coordinating the sharing of 
such information among task forces; 
(E) the nature and extent of cooperation 
by each Federal, State, local, and Tribal partic-
ipant in ensuring that such information is 
shared among law enforcement agencies and 
with the high intensity drug trafficking area; 
(F) the nature and extent to which infor-
mation sharing and enforcement activities are 
coordinated with joint terrorism task forces in 
the high intensity drug trafficking area; and 
(G) any recommendations for measures 
needed to ensure that task force resources are 
utilized efficiently and effectively to reduce the 
availability of illegal drugs in the high intensity 
drug trafficking areas; and
150 
(5) in consultation with the Director of Na-
tional Intelligence— 
(A) evaluates existing and planned law en-
forcement intelligence systems supported by 
such high intensity drug trafficking area, or 
utilized by task forces receiving any funding 
under the Program, including the extent to 
which such systems ensure access and avail-
ability of law enforcement intelligence to Fed-
eral, State, local, and Tribal law enforcement 
agencies within the high intensity drug traf-
ficking area and outside of such area; 
(B) evaluates the extent to which Federal, 
State, local, and Tribal law enforcement agen-
cies participating in each high intensity drug 
trafficking area are sharing law enforcement in-
telligence information to assess current drug 
trafficking threats and design appropriate en-
forcement strategies; and 
(C) identifies the measures needed to im-
prove effective sharing of information and law 
enforcement intelligence regarding drug traf-
ficking and drug production among Federal, 
State, local, and Tribal law enforcement partici-
pating in a high intensity drug trafficking area,
151 
and between such agencies and similar agencies 
outside the high intensity drug trafficking area. 
(l) COORDINATION OF LAW ENFORCEMENT INTEL-
LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN-
FORCEMENT TASK FORCE PROGRAM.— 
(1) DRUG ENFORCEMENT INTELLIGENCE SHAR-
ING.—The Director, in consultation with the Attor-
ney General, shall ensure that any drug enforcement 
intelligence obtained by the Intelligence Support 
Center for each high intensity drug trafficking area 
is shared, on a timely basis, with the drug intel-
ligence fusion center operated by the Organized 
Crime Drug Enforcement Task Force of the Depart-
ment of Justice. 
(2) 
CERTIFICATION.—Before 
the 
Director 
awards any funds to a high intensity drug traf-
ficking area, the Director shall certify that the law 
enforcement entities participating in that HIDTA 
are providing laboratory seizure data to the national 
clandestine laboratory database at the El Paso Intel-
ligence Center. 
(m) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out 
this section $280 million for each fiscal years 2019 
through 2023.
152 
(n) SPECIFIC PURPOSES.— 
(1) IN GENERAL.—The Director shall ensure 
that, of the amounts appropriated for a fiscal year 
for the Program, at least 2.5 percent is used in high 
intensity drug trafficking areas with severe neigh-
borhood safety and illegal drug distribution prob-
lems. 
(2) REQUIRED USES.—The funds used under 
paragraph (1) shall be used to ensure the safety of 
neighborhoods and the protection of communities, 
including the prevention of the intimidation of wit-
nesses of illegal drug distribution and related activi-
ties and the establishment of or support for pro-
grams that provide protection or assistance to wit-
nesses in court proceedings. 
(3) BEST
PRACTICE
MODELS.—The Director 
shall work with the HIDTAs to develop and main-
tain best practice models to assist State, local, and 
Tribal governments in addressing witness safety, re-
location, financial and housing assistance, or any 
other services related to witness protection or assist-
ance in cases of illegal drug distribution and related 
activities. The Director shall ensure dissemination of 
the best practice models to each HIDTA.
153 
SEC. 4. OPIOID CRISIS RESPONSE. 
(a) EMERGING THREAT DESIGNATION.—The Direc-
tor shall designate opioids and opioid analogues as emerg-
ing drug threats, in accordance with section 1009 of title 
31, United States Code, as added by section 2(c). 
(b) OPIOID RESPONSE PLAN.— 
(1) ISSUANCE.—Not later than 60 days after 
the date of the enactment of this Act, the Director 
shall publish, make publicly available, and notify the 
President and the appropriate congressional commit-
tees of, the plan required under section 1009 of title 
31, United States Code, as added by section 2(c), to 
be designated as the ‘‘National Opioid Crisis Re-
sponse Plan’’. 
(2) CONTENTS.—The Director shall ensure the 
plan establishes measurable goals, including reduc-
ing fatal and non-fatal overdoses, and includes the 
following: 
(A) An initiative to ensure the United 
States mail is effectively screened to prevent il-
licit drugs from entering the United States, in-
cluding— 
(i) designating the United States 
Postal Service as a National Drug Control 
Program Agency;
154 
(ii) directing the United States Postal 
Service and any other related National 
Drug Control Program Agency to take any 
appropriate actions necessary to reduce the 
amount of illicit drugs entering the coun-
try; and 
(iii) developing an international co-
ordination plan, in consultation with the 
National Drug Control Program Agencies 
and in accordance with section 1010 of 
such title 31, United States Code, as 
added by section 2(c), to include efforts to 
address international drug control initia-
tives and strengthen bilateral and multilat-
eral strategies to reduce illicit drugs and 
precursor chemicals from entering the 
United States through international mail 
or across land borders or ports of entry. 
(B) Support for universal adoption of evi-
dence-based prescribing guidelines, including— 
(i) establishing a task force to supple-
ment existing prescribing guidelines with 
evidence-based standards and to facilitate, 
coordinate, and, as appropriate, conduct 
research to inform such guidelines;
155 
(ii) encouraging the adoption of evi-
dence-based prescribing guidelines by each 
relevant agency, State and local govern-
ments, and private sector organizations; 
(iii) issuing guidance to National 
Drug Control Program Agencies to, as ap-
propriate, revise regulations to ensure pro-
fessionals have effective continuing edu-
cation requirements; and 
(iv) disseminating and encouraging 
the adoption of best practices and evi-
dence-based guidelines for effective pre-
scribing practices. 
(C) A program to monitor the prescription 
drug market and illicit drug market for changes 
in trends relevant to reducing the supply or de-
mand of such drugs. 
(D) An initiative to facilitate and coordi-
nate Federal, State and local government initia-
tives, studies, and pilot or demonstration pro-
grams designed to evaluate the benefits of drug 
courts and related programs that reduce sub-
stance use prevalence. 
(E) A program, developed in coordination 
with the private sector, to—
156 
(i) facilitate the development of treat-
ment and abuse-deterrent products, in ac-
cordance with section 1010(c) of title 31, 
United States Code, as added by section 
2(c); and 
(ii) encourage the expansion of medi-
cation disposal programs and technology. 
(F) Initiatives to— 
(i) encourage the National Drug Con-
trol Program Agencies and the program 
established under section 1010(d) of title 
31, United States Code, as added by sec-
tion 2(c), to prioritize the development of 
sentencing standards or model codes for 
trafficking opioids and opioid analogues; 
and 
(ii) to advise States on establishing 
laws and policies to address opioid issues 
based on the recommendations developed 
and set forth by the President’s Commis-
sion on Combating Drug Addiction and the 
Opioid Crisis. 
(G) A program to identify successful col-
lege recovery programs, including sober housing 
programs that provide a shared living residence
157 
free of alcohol or illicit drug use for individuals 
recovering from drug or alcohol addiction and 
substance use disorders, on college campuses 
and disseminate best practices to Colleges and 
Universities to increase the number and capac-
ity of such programs. 
(H) Convening working groups, consisting 
of the appropriate National Drug Control Pro-
gram Agencies, State, local and Tribal govern-
ments, and other appropriate stakeholders, es-
tablished in accordance with section 1010 of 
title 31, United States Code, as added by sec-
tion 2(c)— 
(i) to support Prescription Drug Mon-
itoring Programs by— 
(I) facilitating the sharing and 
interoperability 
of 
program 
data 
among States and Federal prescrip-
tion drug monitoring programs; 
(II) assisting States in increasing 
utilization of such programs; 
(III) facilitating efforts to incor-
porate 
available 
overdose 
and 
naloxone deployment data into such 
programs;
158 
(IV) evaluating barriers to inte-
grating program data with electronic 
health records; and 
(V) offering recommendations to 
address identified barriers; and 
(ii) to develop standards, and encour-
age the use of such standards, for the col-
lection of data necessary to understand 
and monitor the opioid crisis, including— 
(I) State medical examiner re-
ports on deaths caused by overdoses 
and related statistical data; and 
(II) first responder opioid intoxi-
cation incidents. 
(I) Research initiatives, to be initiated not 
later than 30 days after the issuance of the 
plan, to evaluate the uses and barriers to use 
of and the effects of improving the following 
programs: 
(i) Medication Assisted Treatment. 
(ii) Data collection systems used to 
confirm opioid use by individuals who have 
been arrested or hospitalized. 
(J) A requirement for an Advisory Com-
mittee on Substance Use Disorder Treatment
159 
Standards, to be established not later than 120 
days after the issuance of the plan, to promul-
gate model evidence-based standards for sub-
stance use disorder treatment and recovery fa-
cilities which— 
(i) shall be chaired by the Director; 
(ii) shall include as members of the 
advisory committee representatives of the 
relevant National Drug Control Program 
Agencies; 
(iii) may include as members of the 
advisory committee government regulators, 
State representatives, consumer represent-
atives, substance use disorder treatment 
providers, recovery residence owners and 
operators, and purchasers of substance use 
disorder treatments; and 
(iv) shall ensure such model standards 
are promulgated no later than 2 years 
after the date of the issuance of the plan. 
(c) RECOMMENDATIONS.—Not later than 1 year after 
the date of the enactment of this Act, the Director shall 
submit to the appropriate congressional committees a re-
port on the results of the initiatives conducted under sub-
160 
section (b)(2)(I) and may include recommendations based 
on such results. 
(d) GRANT REPORT TO CONGRESS.—Not later than 
1 year after the date of the enactment of this Act, the 
Director shall submit to the appropriate congressional 
committees an assessment on the feasibility of block 
grants of Federal funding to States. 
SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION. 
(a) INAPPLICABILITY TO CERTAIN PROGRAMS.—This 
Act, and the amendments made by this Act, shall not 
apply to the National Intelligence Program and the Mili-
tary Intelligence Program, unless such program or an ele-
ment of such program is designated as a National Drug 
Control Program— 
(1) by the President; or 
(2) jointly by— 
(A) in the case of the National Intelligence 
Program, the Director and the Director of Na-
tional Intelligence; or 
(B) in the case of the Military Intelligence 
Program, the Director, the Director of National 
Intelligence, and the Secretary of Defense. 
(b) CLASSIFIED INFORMATION.—Any contents of any 
report required under this Act, or the amendments made 
by this Act, that involve information properly classified
161 
under criteria established by an Executive order shall be 
presented to Congress separately from the rest of such re-
port. 
(c) USE OF EXISTING RESOURCES.—To the extent 
practicable, the Director and the head of each agency shall 
use existing procedures and systems to carry out agency 
requirements under this Act, and the amendments made 
by this Act. 
SEC. 6. GAO AUDIT AND REPORTS. 
Not later than 3 and 6 years after the date of the 
enactment of this Act, the Comptroller General shall— 
(1) conduct an audit relating to the programs 
and operations of— 
(A) the Office; and 
(B) certain programs within the Office, in-
cluding— 
(i) the High Intensity Drug Traf-
ficking Areas Program; 
(ii) the Drug-Free Communities Pro-
gram; and 
(iii) the campaign under section 
1009(d) of title 31, as added by section 
2(c); and
162 
(2) submit to the Director and the appropriate 
congressional committees a report containing an 
evaluation of and recommendations on the— 
(A) policies and activities of the programs 
and operations subject to the audit; 
(B) economy, efficiency, and effectiveness 
in the administration of the reviewed programs 
and operations; and 
(C) policy or management changes needed 
to prevent and detect fraud and abuse in such 
programs and operations. 
SEC. 7. REPEALS. 
(a) REPEALS TO THE LAW.—The following provisions 
are repealed: 
(1) The Office of National Drug Control Policy 
Reauthorization Act of 1998 (Public Law 105–277; 
21 U.S.C. 1701 et seq.). 
(2) Chapter 2 of the National Narcotics Lead-
ership Act of 1988 (Public Law 100–690; 21 U.S.C. 
1501 et seq.). 
(3) Section 203 of the Office of National Drug 
Control Policy Reauthorization Act of 2006 (Public 
Law 109–469; 21 U.S.C. 1708a).
163 
(4) Section 1105 of the Office of National Drug 
Control Policy Reauthorization Act of 2006 (Public 
Law 109–469; 21 U.S.C. 1701 note). 
(5) Section 1110 of Office of National Drug 
Control Policy Reauthorization Act of 2006 (Public 
Law 109–469; 21 U.S.C. 1705 note). 
(6) Section 1110A of the Office of National 
Drug Control Policy Reauthorization Act of 2006 
(Public Law 109–469; 21 U.S.C. 1705 note). 
(7) Section 4 of Public Law 107–82 (21 U.S.C. 
1521 note). 
(b) EFFECT
ON
THE CODE.—The Law Revision 
Counsel shall ensure that the website and any other publi-
cation issued after the date of the enactment of this Act 
for the Office of the Law Revision Counsel shows that the 
laws reflected in subchapter II of chapter 20 and chapter 
22 of nonpositive law title 21 of the United States Code 
have been repealed. 
SEC. 8. DEFINITIONS. 
In this Act, the terms ‘‘agency’’, ‘‘appropriate con-
gressional committees’’, ‘‘Director’’, ‘‘drug’’, ‘‘emerging 
drug threat’’, ‘‘illicit drug use’’, ‘‘illicit drugs’’, ‘‘National 
Drug Control Program Agencies’’, and ‘‘Office’’ have the
164 
meaning given those terms in section 1001 of title 31, 
United States Code, as added by section 2(c). 
Passed the House of Representatives June 20, 2018. 
Attest: 
Clerk.
115TH CONGRESS 
2D SESSION 
H. R. 5925 
AN ACT 
To codify provisions relating to the Office of 
National Drug Control, and for other purposes.